JP7399866B2 - CARTyrin組成物とその利用方法 - Google Patents
CARTyrin組成物とその利用方法 Download PDFInfo
- Publication number
- JP7399866B2 JP7399866B2 JP2020546322A JP2020546322A JP7399866B2 JP 7399866 B2 JP7399866 B2 JP 7399866B2 JP 2020546322 A JP2020546322 A JP 2020546322A JP 2020546322 A JP2020546322 A JP 2020546322A JP 7399866 B2 JP7399866 B2 JP 7399866B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- amino acid
- acid sequence
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 113
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 333
- 210000004027 cell Anatomy 0.000 claims description 284
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 178
- 238000000034 method Methods 0.000 claims description 118
- 241000282414 Homo sapiens Species 0.000 claims description 88
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 72
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 70
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 70
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 50
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 43
- 150000007523 nucleic acids Chemical group 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 37
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 210000005259 peripheral blood Anatomy 0.000 claims description 32
- 239000011886 peripheral blood Substances 0.000 claims description 32
- 230000000139 costimulatory effect Effects 0.000 claims description 31
- 210000002865 immune cell Anatomy 0.000 claims description 30
- 230000003834 intracellular effect Effects 0.000 claims description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 21
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 21
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 21
- 108010068032 caltractin Proteins 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 13
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 13
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 13
- 210000000822 natural killer cell Anatomy 0.000 claims description 10
- 210000004700 fetal blood Anatomy 0.000 claims description 7
- 101100273713 Homo sapiens CD2 gene Proteins 0.000 claims description 6
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 6
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 6
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 6
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 description 325
- 102000008579 Transposases Human genes 0.000 description 310
- 108010020764 Transposases Proteins 0.000 description 309
- 235000001014 amino acid Nutrition 0.000 description 190
- 108090000765 processed proteins & peptides Proteins 0.000 description 156
- 108090000623 proteins and genes Proteins 0.000 description 104
- 230000001939 inductive effect Effects 0.000 description 71
- 102000004196 processed proteins & peptides Human genes 0.000 description 69
- 230000006052 T cell proliferation Effects 0.000 description 68
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 65
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 63
- 229920001184 polypeptide Polymers 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 53
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 52
- 239000004474 valine Substances 0.000 description 52
- 230000014509 gene expression Effects 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 51
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 47
- 108091008874 T cell receptors Proteins 0.000 description 41
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 41
- 108020003175 receptors Proteins 0.000 description 41
- 102000005962 receptors Human genes 0.000 description 40
- 230000027455 binding Effects 0.000 description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 36
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 35
- 229930182817 methionine Natural products 0.000 description 35
- 230000000861 pro-apoptotic effect Effects 0.000 description 34
- 239000002609 medium Substances 0.000 description 33
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 33
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 31
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 31
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 31
- 239000005642 Oleic acid Substances 0.000 description 31
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 31
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 31
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 31
- 102000004039 Caspase-9 Human genes 0.000 description 30
- 108090000566 Caspase-9 Proteins 0.000 description 30
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 30
- 235000021314 Palmitic acid Nutrition 0.000 description 30
- 235000004279 alanine Nutrition 0.000 description 30
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 30
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 29
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 28
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 28
- 239000004472 Lysine Substances 0.000 description 28
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 28
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 28
- 239000003446 ligand Substances 0.000 description 28
- 229960004488 linolenic acid Drugs 0.000 description 28
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 28
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 28
- 229960005190 phenylalanine Drugs 0.000 description 28
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 27
- 230000004913 activation Effects 0.000 description 27
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 26
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 26
- 229930182558 Sterol Natural products 0.000 description 26
- 150000003432 sterols Chemical class 0.000 description 26
- 235000003702 sterols Nutrition 0.000 description 26
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 25
- -1 IL14 Proteins 0.000 description 24
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 24
- 102000011727 Caspases Human genes 0.000 description 23
- 108010076667 Caspases Proteins 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- 239000004475 Arginine Substances 0.000 description 22
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 22
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 22
- 210000000130 stem cell Anatomy 0.000 description 22
- 210000003071 memory t lymphocyte Anatomy 0.000 description 21
- 230000004083 survival effect Effects 0.000 description 21
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 20
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 20
- 229960001230 asparagine Drugs 0.000 description 20
- 235000009582 asparagine Nutrition 0.000 description 20
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 20
- 229960000310 isoleucine Drugs 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 20
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 19
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 239000013589 supplement Substances 0.000 description 19
- 239000004471 Glycine Substances 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 18
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 17
- 238000010586 diagram Methods 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 240000007019 Oxalis corniculata Species 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 15
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 15
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 15
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 15
- 230000010261 cell growth Effects 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 15
- 239000002539 nanocarrier Substances 0.000 description 14
- LXOFYPKXCSULTL-UHFFFAOYSA-N 2,4,7,9-tetramethyldec-5-yne-4,7-diol Chemical compound CC(C)CC(C)(O)C#CC(C)(O)CC(C)C LXOFYPKXCSULTL-UHFFFAOYSA-N 0.000 description 13
- IPRJXAGUEGOFGG-UHFFFAOYSA-N N-butylbenzenesulfonamide Chemical compound CCCCNS(=O)(=O)C1=CC=CC=C1 IPRJXAGUEGOFGG-UHFFFAOYSA-N 0.000 description 13
- 239000000556 agonist Substances 0.000 description 13
- 108091035707 Consensus sequence Proteins 0.000 description 12
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 12
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 239000013603 viral vector Substances 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 11
- 108010022394 Threonine synthase Proteins 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 235000018417 cysteine Nutrition 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 10
- 241000702421 Dependoparvovirus Species 0.000 description 10
- 102000002090 Fibronectin type III Human genes 0.000 description 10
- 108050009401 Fibronectin type III Proteins 0.000 description 10
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 10
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 10
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 10
- 102100033467 L-selectin Human genes 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 229940031578 diisopropyl adipate Drugs 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 10
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 102000006306 Antigen Receptors Human genes 0.000 description 9
- 108010083359 Antigen Receptors Proteins 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 9
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
- 239000004473 Threonine Substances 0.000 description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 9
- 229960002743 glutamine Drugs 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 102220236765 rs80358547 Human genes 0.000 description 9
- 238000012447 xenograft mouse model Methods 0.000 description 9
- 108010042634 F2A4-K-NS peptide Proteins 0.000 description 8
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 description 8
- 102000013691 Interleukin-17 Human genes 0.000 description 8
- 108050003558 Interleukin-17 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 101800001494 Protease 2A Proteins 0.000 description 8
- 101800001066 Protein 2A Proteins 0.000 description 8
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 239000002458 cell surface marker Substances 0.000 description 8
- MGWAVDBGNNKXQV-UHFFFAOYSA-N diisobutyl phthalate Chemical compound CC(C)COC(=O)C1=CC=CC=C1C(=O)OCC(C)C MGWAVDBGNNKXQV-UHFFFAOYSA-N 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- BYTFESSQUGDMQQ-UHFFFAOYSA-N octadecanehydrazide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NN BYTFESSQUGDMQQ-UHFFFAOYSA-N 0.000 description 8
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 238000005415 bioluminescence Methods 0.000 description 7
- 230000029918 bioluminescence Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 102000003675 cytokine receptors Human genes 0.000 description 7
- 108010057085 cytokine receptors Proteins 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 102000004419 dihydrofolate reductase Human genes 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102100040069 Aldehyde dehydrogenase 1A1 Human genes 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 6
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 description 6
- 102000009410 Chemokine receptor Human genes 0.000 description 6
- 108050000299 Chemokine receptor Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 6
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 6
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 102000003812 Interleukin-15 Human genes 0.000 description 6
- 108090000172 Interleukin-15 Proteins 0.000 description 6
- 102100030704 Interleukin-21 Human genes 0.000 description 6
- 102100039064 Interleukin-3 Human genes 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 102000000743 Interleukin-5 Human genes 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 108700041567 MDR Genes Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- 102000038030 PI3Ks Human genes 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 108091000114 ceramide glucosyltransferase Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000006274 endogenous ligand Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 108010074108 interleukin-21 Proteins 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 235000021313 oleic acid Nutrition 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 235000004252 protein component Nutrition 0.000 description 6
- 102200015453 rs121912293 Human genes 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- LQERIDTXQFOHKA-UHFFFAOYSA-N nonadecane Chemical compound CCCCCCCCCCCCCCCCCCC LQERIDTXQFOHKA-UHFFFAOYSA-N 0.000 description 5
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 4
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 4
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 4
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 102000013264 Interleukin-23 Human genes 0.000 description 4
- 108010065637 Interleukin-23 Proteins 0.000 description 4
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 102100033501 Interleukin-32 Human genes 0.000 description 4
- 102000017761 Interleukin-33 Human genes 0.000 description 4
- 108010067003 Interleukin-33 Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 4
- 102000008072 Lymphokines Human genes 0.000 description 4
- 108010074338 Lymphokines Proteins 0.000 description 4
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 4
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000005775 apoptotic pathway Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229940076264 interleukin-3 Drugs 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 229940100994 interleukin-7 Drugs 0.000 description 4
- 150000002614 leucines Chemical class 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 3
- NSBGUMKAXUXKGI-BPNHAYRBSA-N AP20187 Chemical compound C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCC(=O)NCC(CNC(=O)COC=2C=C(C=CC=2)[C@@H](CCC=2C=C(OC)C(OC)=CC=2)OC(=O)[C@H]2N(CCCC2)C(=O)[C@@H](CC)C=2C=C(OC)C(OC)=C(OC)C=2)CN(C)C)C=CC=1)CC1=CC=C(OC)C(OC)=C1 NSBGUMKAXUXKGI-BPNHAYRBSA-N 0.000 description 3
- 101710150756 Aldehyde dehydrogenase, mitochondrial Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
- 241001367013 Ctenoplusia agnata Species 0.000 description 3
- 230000008836 DNA modification Effects 0.000 description 3
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 3
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 3
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 3
- 101000890570 Homo sapiens Aldehyde dehydrogenase 1A1 Proteins 0.000 description 3
- 101000632186 Homo sapiens Homeobox protein Nkx-2.2 Proteins 0.000 description 3
- 101100460496 Homo sapiens NKX2-2 gene Proteins 0.000 description 3
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
- 101001124667 Homo sapiens Proteasome subunit alpha type-5 Proteins 0.000 description 3
- 101000612692 Homo sapiens Proteasome subunit alpha-type 8 Proteins 0.000 description 3
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 108010076693 O(6)-Methylguanine-DNA Methyltransferase Proteins 0.000 description 3
- 102100029270 Proteasome subunit alpha type-5 Human genes 0.000 description 3
- 102100040972 Proteasome subunit alpha-type 8 Human genes 0.000 description 3
- 102000005497 Thymidylate Synthase Human genes 0.000 description 3
- 102100038618 Thymidylate synthase Human genes 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000001099 axilla Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 210000004986 primary T-cell Anatomy 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 102000027257 transmembrane receptors Human genes 0.000 description 3
- 108091008578 transmembrane receptors Proteins 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- RSNQVABHABAKEZ-UHFFFAOYSA-N 2,3-diphenylquinoxaline Chemical class C1=CC=CC=C1C1=NC2=CC=CC=C2N=C1C1=CC=CC=C1 RSNQVABHABAKEZ-UHFFFAOYSA-N 0.000 description 2
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 description 2
- 108060000255 AIM2 Proteins 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 108090000663 Annexin A1 Proteins 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 2
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101150057924 Exoc2 gene Proteins 0.000 description 2
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 2
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 description 2
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 description 2
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 2
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 description 2
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 2
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 2
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 2
- 101710090028 Inositol-3-phosphate synthase 1 Proteins 0.000 description 2
- 102100032816 Integrin alpha-6 Human genes 0.000 description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 2
- 108010032036 Interferon Regulatory Factor-7 Proteins 0.000 description 2
- 102100020990 Interferon lambda-1 Human genes 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 2
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102100033461 Interleukin-17A Human genes 0.000 description 2
- 102100039879 Interleukin-19 Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102100030692 Interleukin-20 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 102100036680 Interleukin-25 Human genes 0.000 description 2
- 102100036679 Interleukin-26 Human genes 0.000 description 2
- 108010066979 Interleukin-27 Proteins 0.000 description 2
- 102100021596 Interleukin-31 Human genes 0.000 description 2
- 108091007973 Interleukin-36 Proteins 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NYJGMJFBEVSQNN-CNRHASOASA-N Medermycin Chemical compound C1[C@@H](N(C)C)[C@H](O)[C@@H](C)O[C@H]1C1=CC=C(C(=O)C=2[C@H]3OC(=O)C[C@H]3O[C@H](C)C=2C2=O)C2=C1O NYJGMJFBEVSQNN-CNRHASOASA-N 0.000 description 2
- 102220596403 Melanocyte-stimulating hormone receptor_V93L_mutation Human genes 0.000 description 2
- 102100023727 Mitochondrial antiviral-signaling protein Human genes 0.000 description 2
- 101710142315 Mitochondrial antiviral-signaling protein Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229920002508 Poloxamer 181 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102220517643 Ras-related protein Rab-33B_Q92A_mutation Human genes 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 2
- 102100024483 Sororin Human genes 0.000 description 2
- 102220466828 Splicing factor U2AF 65 kDa subunit_P96G_mutation Human genes 0.000 description 2
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 2
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 2
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 2
- 102100027188 Thyroid peroxidase Human genes 0.000 description 2
- 101710113649 Thyroid peroxidase Proteins 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 102000044880 Wnt3A Human genes 0.000 description 2
- 108700013515 Wnt3A Proteins 0.000 description 2
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 2
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 2
- 239000007825 activation reagent Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229930192649 bafilomycin Natural products 0.000 description 2
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 108010010804 beta2 Heterotrimer Lymphotoxin alpha1 Proteins 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 102000055276 human IL3 Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical class C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 102000003898 interleukin-24 Human genes 0.000 description 2
- 108090000237 interleukin-24 Proteins 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 229950006331 ipatasertib Drugs 0.000 description 2
- 229940099584 lactobionate Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 2
- 229960003775 miltefosine Drugs 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940085692 poloxamer 181 Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 102200148948 rs104893714 Human genes 0.000 description 2
- 102220125775 rs541257103 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 2
- 229950003873 triciribine Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- YWTBGJGMTBHQTM-IBGZPJMESA-N (2S)-1-(1H-indol-3-yl)-3-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-2-propanamine Chemical compound C1=CC=C2C(C[C@H](N)COC=3C=NC=C(C=3)C3=CC=C4NN=C(C4=C3)C)=CNC2=C1 YWTBGJGMTBHQTM-IBGZPJMESA-N 0.000 description 1
- BPNUQXPIQBZCMR-IBGZPJMESA-N (2s)-1-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}-3-phenylpropan-2-amine Chemical compound C([C@H](N)COC=1C=NC=C(C=1)C1=CC=C2NN=C(C2=C1)C)C1=CC=CC=C1 BPNUQXPIQBZCMR-IBGZPJMESA-N 0.000 description 1
- XLPAINGDLCDYQV-SDTWUMECSA-N (2s)-6-methyl-2-[(5r,10s,13s,14s,17s)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-5-enoic acid Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CCC1=C2CC[C@@]2(C)[C@H]([C@H](CCC=C(C)C)C(O)=O)CC[C@@]21C XLPAINGDLCDYQV-SDTWUMECSA-N 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- AOYBLZGEIIBUTE-UHFFFAOYSA-N 1,2,5-oxadiazol-3-amine Chemical compound NC=1C=NON=1 AOYBLZGEIIBUTE-UHFFFAOYSA-N 0.000 description 1
- MHFRGQHAERHWKZ-UHFFFAOYSA-N 1-octadecyl-2-methylglycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- ZQKMVHXJWJNEQG-UHFFFAOYSA-N 1h-1,6-naphthyridin-2-one Chemical class C1=NC=CC2=NC(O)=CC=C21 ZQKMVHXJWJNEQG-UHFFFAOYSA-N 0.000 description 1
- JBGYKRAZYDNCNV-UHFFFAOYSA-N 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide Chemical compound N12N=C(C(=O)N)C=CC2=NC(C=2C=CC(=CC=2)C2(N)CCC2)=C1C1=CC=CC=C1 JBGYKRAZYDNCNV-UHFFFAOYSA-N 0.000 description 1
- LLZQFAXTCYDVTR-UHFFFAOYSA-N 2-chloro-1-(1h-indol-3-yl)ethanone Chemical compound C1=CC=C2C(C(=O)CCl)=CNC2=C1 LLZQFAXTCYDVTR-UHFFFAOYSA-N 0.000 description 1
- BDPQVGIMLZYZQA-UHFFFAOYSA-N 2-hexadecanoylthio-1-ethylphosphorylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)SCCOP([O-])(=O)OCC[N+](C)(C)C BDPQVGIMLZYZQA-UHFFFAOYSA-N 0.000 description 1
- VFTRKSBEFQDZKX-UHFFFAOYSA-N 3,3'-diindolylmethane Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4NC=3)=CNC2=C1 VFTRKSBEFQDZKX-UHFFFAOYSA-N 0.000 description 1
- IWCQHVUQEFDRIW-UHFFFAOYSA-N 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(cc2)-c2[nH]c3cc4ncnc4cc3nc2-c2ccccc2)CC1 IWCQHVUQEFDRIW-UHFFFAOYSA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- AGQWNWPWJSILEU-UHFFFAOYSA-N 3-phenylimidazo[4,5-b]pyridine Chemical class C1=NC2=CC=CN=C2N1C1=CC=CC=C1 AGQWNWPWJSILEU-UHFFFAOYSA-N 0.000 description 1
- RZIDZIGAXXNODG-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine Chemical compound C1CN(C=2C=3C=CNC=3N=CN=2)CCC1(N)CC1=CC=C(Cl)C=C1 RZIDZIGAXXNODG-UHFFFAOYSA-N 0.000 description 1
- SPBWHPXCWJLQRU-FITJORAGSA-N 4-amino-8-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound C12=NC=NC(N)=C2C(=O)C(C(=O)N)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SPBWHPXCWJLQRU-FITJORAGSA-N 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- BYWWNRBKPCPJMG-UHFFFAOYSA-N 4-dodecyl-n-(1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(CCCCCCCCCCCC)=CC=C1S(=O)(=O)NC1=NN=CS1 BYWWNRBKPCPJMG-UHFFFAOYSA-N 0.000 description 1
- YTQFOPPEYLNRJT-UHFFFAOYSA-N 6-phenyl-7h-purine Chemical class C=12NC=NC2=NC=NC=1C1=CC=CC=C1 YTQFOPPEYLNRJT-UHFFFAOYSA-N 0.000 description 1
- 241000253994 Acyrthosiphon pisum Species 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 101710097510 Beta-lactamase SHV-1 Proteins 0.000 description 1
- 241000906071 Bombus impatiens Species 0.000 description 1
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 241000426497 Chilo suppressalis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251571 Ciona intestinalis Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 241001494242 Daphnia pulicaria Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- DFLGVVQWXYTGFU-UHFFFAOYSA-N Frenolicin B Natural products CCCC1OC2CC(=O)OC2C3C1C(=O)c4c(O)cccc4C3=O DFLGVVQWXYTGFU-UHFFFAOYSA-N 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- 102000038624 GSKs Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 241001147381 Helicoverpa armigera Species 0.000 description 1
- 241000256244 Heliothis virescens Species 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 229930188887 Lactoquinomycin Natural products 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000317321 Macdunnoughia crassisigna Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000555303 Mamestra brassicae Species 0.000 description 1
- 241001422926 Mayetiola hordei Species 0.000 description 1
- 241001279692 Megachile rotundata Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000608621 Myotis lucifugus Species 0.000 description 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 description 1
- QIBNBZMEQZMQJG-UHFFFAOYSA-N OC1=CC=CC=C1C1=NNC=C1C1=CC=CCC1 Chemical compound OC1=CC=CC=C1C1=NNC=C1C1=CC=CCC1 QIBNBZMEQZMQJG-UHFFFAOYSA-N 0.000 description 1
- VTAZRSXSBIHBMH-UHFFFAOYSA-N Ophiocordin Natural products OC1=CC(C(=O)O)=CC(O)=C1C(=O)C1=C(O)C=CC=C1C(=O)NC1C(OC(=O)C=2C=CC(O)=CC=2)CCCNC1 VTAZRSXSBIHBMH-UHFFFAOYSA-N 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241000721451 Pectinophora gossypiella Species 0.000 description 1
- XLPAINGDLCDYQV-UHFFFAOYSA-N Pinicolsaeure Natural products CC12CCC(=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)CCC21C XLPAINGDLCDYQV-UHFFFAOYSA-N 0.000 description 1
- 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 description 1
- 101710129981 Pituitary-specific positive transcription factor 1 Proteins 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000001999 Transcription Factor Pit-1 Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 241000254113 Tribolium castaneum Species 0.000 description 1
- 241000269457 Xenopus tropicalis Species 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001537 azepanes Chemical class 0.000 description 1
- XYUFCXJZFZPEJD-XMSQKQJNSA-N balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-XMSQKQJNSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000012777 commercial manufacturing Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GDPJWJXLKPPEKK-SJAYXVESSA-N dT4 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 GDPJWJXLKPPEKK-SJAYXVESSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- TWJAXIHBWPVMIR-UHFFFAOYSA-N diindolylmethane Natural products C1=CC=C2NC(CC=3NC4=CC=CC=C4C=3)=CC2=C1 TWJAXIHBWPVMIR-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950011461 edelfosine Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- AVCPRTNVVRPELB-YRUZYCQGSA-N frenolicin B Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](CCC)O[C@H]1[C@@H]2OC(=O)C1 AVCPRTNVVRPELB-YRUZYCQGSA-N 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229950006905 ilmofosine Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 235000002279 indole-3-carbinol Nutrition 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000004272 isoquinoline-5-sulfonamides Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- CGWBCAQMXJFWBU-UHFFFAOYSA-N n-[(2-hydroxy-5-nitrophenyl)carbamothioyl]-3,5-dimethylbenzamide Chemical compound CC1=CC(C)=CC(C(=O)NC(=S)NC=2C(=CC=C(C=2)[N+]([O-])=O)O)=C1 CGWBCAQMXJFWBU-UHFFFAOYSA-N 0.000 description 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 description 1
- RIGXBXPAOGDDIG-UHFFFAOYSA-N n-[(3-chloro-2-hydroxy-5-nitrophenyl)carbamothioyl]benzamide Chemical compound OC1=C(Cl)C=C([N+]([O-])=O)C=C1NC(=S)NC(=O)C1=CC=CC=C1 RIGXBXPAOGDDIG-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 150000008048 phenylpyrazoles Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000575 polymersome Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- QZILSYOEHMXZBE-UHFFFAOYSA-N pyrido[2,3-d]pyrimidin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=N1 QZILSYOEHMXZBE-UHFFFAOYSA-N 0.000 description 1
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 1
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical class NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464495—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Description
本出願は、2018年3月7日に出願されたアメリカ合衆国仮出願第62/639,978号と、2018年10月12日に出願されたアメリカ合衆国仮出願第62/745,151号と、2018年12月20日に出願されたアメリカ合衆国仮出願第62/783,140号の優先権の恩恵を主張するものであり、そのそれぞれの内容の全体が参照によって本明細書に組み込まれている。
参照による配列リストの組み込み
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)と少なくとも75%、80%、85%、90%、95%、97%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)の30位、165位、282位、538位のうちの1つ以上にアミノ酸置換を有するアミノ酸配列を含むか、このアミノ酸配列からなるpiggyBac(商標)(PB)トランスポザーゼ酵素である。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPKEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14484)と少なくとも70%、80%、90%、95%、99%、またはこれらの数値の間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることが可能である。
MMLNWLKSGK LESQSQEQSS CYLENSNCLP PTLDSTDIIG EENKAGTTSR KKRKYDEDYL
NFGFTWTGDK DEPNGLCVIC EQVVNNSSLN PAKLKRHLDT KHPTLKGKSE YFKRKCNELN
QKKHTFERYV RDDNKNLLKA SYLVSLRIAK QGEAYTIAEK LIKPCTKDLT TCVFGEKFAS
KVDLVPLSDT TISRRIEDMS YFCEAVLVNR LENAKCGFTL QMDESTDVAG LAILLVFVRY
IHESSFEEDM LFCKALPTQT TGEEIFNLLN AYFEKHSIPW NLCYHICTDG AKAMVGVIKG
VIARIKKLVP DIKASHCCLH RHALAVKRIP NALHEVLNDA VKMINFIKSR PLNARVFALL
CDDLGSLHKN LLLHTEVRWL SRGKVLTRFW ELRDEIRIFF NEREFAGKLN DTSWLQNLAY
IADIFSYLNE VNLSLQGPNS TIFKVNSRIN SIKSKLKLWE ECITKNNTEC FANLNDFLET
SNTALDPNLK SNILEHLNGL KNTFLEYFPP TCNNISWVEN PFNECGNVDT LPIKEREQLI
DIRTDTTLKS SFVPDGIGPF WIKLMDEFPE ISKRAVKELM PFVTTYLCEK SFSVYVATKT
KYRNRLDAED DMRLQLTTIH PDIDNLCNNK QAQKSH(配列番号17900)と少なくとも75%一致する配列を含んでいる。
GS(配列番号18028)を含むアミノ酸、またはGGAGGAGGAGGATCC(配列番号18029)を含む核酸配列によってコードされている。いくつかの実施態様では、リンカーをコードする核酸配列は制限部位を含まない。
SPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSGFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGLRTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTS(配列番号18032)を含むアミノ酸配列、またはggggtccaggtcgagactatttcaccaggggatgggcgaacatttccaaaaaggggccagacttgcgtcgtgcattacaccgggatgctggaggacgggaagaaagtggacagctccagggatcgcaacaagcccttcaagttcatgctgggaaagcaggaagtgatccgaggatgggaggaaggcgtggcacagatgtcagtcggccagcgggccaaactgaccattagccctgactacgcttatggagcaacaggccacccagggatcattccccctcatgccaccctggtcttcgatgtggaactgctgaagctggagggaggaggaggatccggatttggggacgtgggggccctggagtctctgcgaggaaatgccgatctggcttacatcctgagcatggaaccctgcggccactgtctgatcattaacaatgtgaacttctgcagagaaagcggactgcgaacacggactggctccaatattgactgtgagaagctgcggagaaggttctctagtctgcactttatggtcgaagtgaaaggggatctgaccgccaagaaaatggtgctggccctgctggagctggctcagcaggaccatggagctctggattgctgcgtggtcgtgatcctgtcccacgggtgccaggcttctcatctgcagttccccggagcagtgtacggaacagacggctgtcctgtcagcgtggagaagatcgtcaacatcttcaacggcacttcttgccctagtctggggggaaagccaaaactgttctttatccaggcctgtggcggggaacagaaagatcacggcttcgaggtggccagcaccagccctgaggacgaatcaccagggagcaaccctgaaccagatgcaactccattccaggagggactgaggacctttgaccagctggatgctatctcaagcctgcccactcctagtgacattttcgtgtcttacagtaccttcccaggctttgtctcatggcgcgatcccaagtcagggagctggtacgtggagacactggacgacatctttgaacagtgggcccattcagaggacctgcagagcctgctgctgcgagtggcaaacgctgtctctgtgaagggcatctacaaacagatgcccgggtgcttcaattttctgagaaagaaactgttctttaagacttcc(配列番号18033)を含む核酸配列によってコードされている。
図面の簡単な説明
細胞組成物のさらなる改変
1 MVGSLNCIVA VSQNMGIGKN GDFPWPPLRN ESRYFQRMTT TSSVEGKQNL
61 VIMGKKTWFS IPEKNRPLKG RINLVLSREL KEPPQGAHFL SRSLDDALKL
121 TEQPELANKV DMVWIVGGSS VYKEAMNHPG HLKLFVTRIM QDFESDTFFP
181 EIDLEKYKLL PEYPGVLSDV QEEKGIKYKF EVYEKND(配列番号17012)のアミノ酸配列を含むか、このアミノ酸配列からなる。いくつかの実施態様では、DHFR突然変異酵素のアミノ酸配列は、80位、113位、153位のうちの1つ以上に変異をさらに含んでいる。いくつかの実施態様では、DHFR突然変異酵素のアミノ酸配列は、80位におけるフェニルアラニン(F)またはロイシン(L)の置換、113位におけるロイシン(L)またはバリン(V)の置換、153位におけるバリン(V)またはアスパラギン酸(D)の置換のうちの1つ以上を含んでいる。
キメラ刺激受容体(CSR)
免疫細胞と免疫前駆細胞
造血幹細胞(HSC)
T細胞
ナチュラルキラー(NK)細胞
B細胞
転移系(トランスポジションシステム)
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)と少なくとも75%、80%、85%、90%、95%、99%、またはこれらの数値の間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)の30位、165位、282位、538位のうちの1つ以上にアミノ酸置換を有するアミノ酸配列を含むか、このアミノ酸配列からなるpiggyBac(商標)(PB)トランスポザーゼ酵素である。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPKEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14484)と少なくとも75%、80%、85%、90%、95%、99%、またはこれらの数値の間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MGKSKEISQD LRKKIVDLHK SGSSLGAISK RLKVPRSSVQ TIVRKYKHHG TTQPSYRSGR
61 RRVLSPRDER TLVRKVQINP RTTAKDLVKM LEETGTKVSI STVKRVLYRH NLKGRSARKK
121 PLLQNRHKKA RLRFATAHGD KDRTFWRNVL WSDETKIELF GHNDHRYVWR KKGEACKPKN
181 TIPTVKHGGG SIMLWGCFAA GGTGALHKID GIMRKENYVD ILKQHLKTSV RKLKLGRKWV
241 FQMDNDPKHT SKVVAKWLKD NKVKVLEWPS QSPDLNPIEN LWAELKKRVR ARRPTNLTQL
301 HQLCQEEWAK IHPTYCGKLV EGYPKRLTQV KQFKGNATKY(配列番号14485)と少なくとも75%、80%、85%、90%、95%、99%、またはこれらの数値の間の任意の割合が一致するアミノ酸配列を含んでいる。
1 MGKSKEISQD LRKRIVDLHK SGSSLGAISK RLAVPRSSVQ TIVRKYKHHG TTQPSYRSGR
61 RRVLSPRDER TLVRKVQINP RTTAKDLVKM LEETGTKVSI STVKRVLYRH NLKGHSARKK
121 PLLQNRHKKA RLRFATAHGD KDRTFWRNVL WSDETKIELF GHNDHRYVWR KKGEACKPKN
181 TIPTVKHGGG SIMLWGCFAA GGTGALHKID GIMDAVQYVD ILKQHLKTSV RKLKLGRKWV
241 FQHDNDPKHT SKVVAKWLKD NKVKVLEWPS QSPDLNPIEN LWAELKKRVR ARRPTNLTQL
301 HQLCQEEWAK IHPNYCGKLV EGYPKRLTQV KQFKGNATKY(配列番号14486)と少なくとも75%、80%、85%、90%、95%、99%、またはこれらの数値の間の任意の割合が一致するアミノ酸配列を含んでいる。
1 TCCTATATAA TAAAAGAGAA ACATGCAAAT TGACCATCCC TCCGCTACGC TCAAGCCACG
61 CCCACCAGCC AATCAGAAGT GACTATGCAA ATTAACCCAA CAAAGATGGC AGTTAAATTT
121 GCATACGCAG GTGTCAAGCG CCCCAGGAGG CAACGGCGGC CGCGGGCTCC CAGGACCTTC
181 GCTGGCCCCG GGAGGCGAGG CCGGCCGCGC CTAGCCACAC CCGCGGGCTC CCGGGACCTT
241 CGCCAGCAGA GAGCAGAGCG GGAGAGCGGG CGGAGAGCGG GAGGTTTGGA GGACTTGGCA
301 GAGCAGGAGG CCGCTGGACA TAGAGCAGAG CGAGAGAGAG GGTGGCTTGG AGGGCGTGGC
361 TCCCTCTGTC ACCCCAGCTT CCTCATCACA GCTGTGGAAA CTGACAGCAG GGAGGAGGAA
421 GTCCCACCCC CACAGAATCA GCCAGAATCA GCCGTTGGTC AGACAGCTCT CAGCGGCCTG
481 ACAGCCAGGA CTCTCATTCA CCTGCATCTC AGACCGTGAC AGTAGAGAGG TGGGACTATG
541 TCTAAAGAAC AACTGTTGAT ACAACGTAGC TCTGCAGCCG AAAGATGCCG GCGTTATCGA
601 CAGAAAATGT CTGCAGAGCA ACGTGCGTCT GATCTTGAAA GAAGGCGGCG CCTGCAACAG
661 AATGTATCTG AAGAGCAGCT ACTGGAAAAA CGTCGCTCTG AAGCCGAAAA ACAGCGGCGT
721 CATCGACAGA AAATGTCTAA AGACCAACGT GCCTTTGAAG TTGAAAGAAG GCGGTGGCGA
781 CGACAGAATA TGTCTAGAGA ACAGTCATCA ACAAGTACTA CCAATACCGG TAGGAACTGC
841 CTTCTCAGCA AAAATGGAGT ACATGAGGAT GCAATTCTCG AACATAGTTG TGGTGGAATG
901 ACTGTTCGAT GTGAATTTTG CCTATCACTA AATTTCTCTG ATGAAAAACC ATCCGATGGG
961 AAATTTACTC GATGTTGTAG CAAAGGGAAA GTCTGTCCAA ATGATATACA TTTTCCAGAT
1021 TACCCGGCAT ATTTAAAAAG ATTAATGACA AACGAAGATT CTGACAGTAA AAATTTCATG
1081 GAAAATATTC GTTCCATAAA TAGTTCTTTT GCTTTTGCTT CCATGGGTGC AAATATTGCA
1141 TCGCCATCAG GATATGGGCC ATACTGTTTT AGAATACACG GACAAGTTTA TCACCGTACT
1201 GGAACTTTAC ATCCTTCGGA TGGTGTTTCT CGGAAGTTTG CTCAACTCTA TATTTTGGAT
1261 ACAGCCGAAG CTACAAGTAA AAGATTAGCA ATGCCAGAAA ACCAGGGCTG CTCAGAAAGA
1321 CTCATGATCA ACATCAACAA CCTCATGCAT GAAATAAATG AATTAACAAA ATCGTACAAG
1381 ATGCTACATG AGGTAGAAAA GGAAGCCCAA TCTGAAGCAG CAGCAAAAGG TATTGCTCCC
1441 ACAGAAGTAA CAATGGCGAT TAAATACGAT CGTAACAGTG ACCCAGGTAG ATATAATTCT
1501 CCCCGTGTAA CCGAGGTTGC TGTCATATTC AGAAACGAAG ATGGAGAACC TCCTTTTGAA
1561 AGGGACTTGC TCATTCATTG TAAACCAGAT CCCAATAATC CAAATGCCAC TAAAATGAAA
1621 CAAATCAGTA TCCTGTTTCC TACATTAGAT GCAATGACAT ATCCTATTCT TTTTCCACAT
1681 GGTGAAAAAG GCTGGGGAAC AGATATTGCA TTAAGACTCA GAGACAACAG TGTAATCGAC
1741 AATAATACTA GACAAAATGT AAGGACACGA GTCACACAAA TGCAGTATTA TGGATTTCAT
1801 CTCTCTGTGC GGGACACGTT CAATCCTATT TTAAATGCAG GAAAATTAAC TCAACAGTTT
1861 ATTGTGGATT CATATTCAAA AATGGAGGCC AATCGGATAA ATTTCATCAA AGCAAACCAA
1921 TCTAAGTTGA GAGTTGAAAA ATATAGTGGT TTGATGGATT ATCTCAAATC TAGATCTGAA
1981 AATGACAATG TGCCGATTGG TAAAATGATA ATACTTCCAT CATCTTTTGA GGGTAGTCCC
2041 AGAAATATGC AGCAGCGATA TCAGGATGCT ATGGCAATTG TAACGAAGTA TGGCAAGCCC
2101 GATTTATTCA TAACCATGAC ATGCAACCCC AAATGGGCAG ATATTACAAA CAATTTACAA
2161 CGCTGGCAAA AAGTTGAAAA CAGACCTGAC TTGGTAGCCA GAGTTTTTAA TATTAAGCTG
2221 AATGCTCTTT TAAATGATAT ATGTAAATTC CATTTATTTG GCAAAGTAAT AGCTAAAATT
2281 CATGTCATTG AATTTCAGAA ACGCGGACTG CCTCACGCTC ACATATTATT GATATTAGAT
2341 AGTGAGTCCA AATTACGTTC AGAAGATGAC ATTGACCGTA TAGTTAAGGC AGAAATTCCA
2401 GATGAAGACC AGTGTCCTCG ACTTTTTCAA ATTGTAAAAT CAAATATGGT ACATGGACCA
2461 TGTGGAATAC AAAATCCAAA TAGTCCATGT ATGGAAAATG GAAAATGTTC AAAGGGATAT
2521 CCAAAAGAAT TTCAAAATGC GACCATTGGA AATATTGATG GATATCCCAA ATACAAACGA
2581 AGATCTGGTA GCACCATGTC TATTGGAAAT AAAGTTGTCG ATAACACTTG GATTGTCCCT
2641 TATAACCCGT ATTTGTGCCT TAAATATAAC TGTCATATAA ATGTTGAAGT CTGTGCATCA
2701 ATTAAAAGTG TCAAATATTT ATTTAAATAC ATCTATAAAG GGCACGATTG TGCAAATATT
2761 CAAATTTCTG AAAAAAATAT TATCAATCAT GACGAAGTAC AGGACTTCAT TGACTCCAGG
2821 TATGTGAGCG CTCCTGAGGC TGTTTGGAGA CTTTTTGCAA TGCGAATGCA TGACCAATCT
2881 CATGCAATCA CAAGATTAGC TATTCATTTG CCAAATGATC AGAATTTGTA TTTTCATACC
2941 GATGATTTTG CTGAAGTTTT AGATAGGGCT AAAAGGCATA ACTCGACTTT GATGGCTTGG
3001 TTCTTATTGA ATAGAGAAGA TTCTGATGCA CGTAATTATT ATTATTGGGA GATTCCACAG
3061 CATTATGTGT TTAATAATTC TTTGTGGACA AAACGCCGAA AGGGTGGGAA TAAAGTATTA
3121 GGTAGACTGT TCACTGTGAG CTTTAGAGAA CCAGAACGAT ATTACCTTAG ACTTTTGCTT
3181 CTGCATGTAA AAGGTGCGAT AAGTTTTGAG GATCTGCGAA CTGTAGGAGG TGTAACTTAT
3241 GATACATTTC ATGAAGCTGC TAAACACCGA GGATTATTAC TTGATGACAC TATCTGGAAA
3301 GATACGATTG ACGATGCAAT CATCCTTAAT ATGCCCAAAC AACTACGGCA ACTTTTTGCA
3361 TATATATGTG TGTTTGGATG TCCTTCTGCT GCAGACAAAT TATGGGATGA GAATAAATCT
3421 CATTTTATTG AAGATTTCTG TTGGAAATTA CACCGAAGAG AAGGTGCCTG TGTGAACTGT
3481 GAAATGCATG CCCTTAACGA AATTCAGGAG GTATTCACAT TGCATGGAAT GAAATGTTCA
3541 CATTTCAAAC TTCCGGACTA TCCTTTATTA ATGAATGCAA ATACATGTGA TCAATTGTAC
3601 GAGCAACAAC AGGCAGAGGT TTTGATAAAT TCTCTGAATG ATGAACAGTT GGCAGCCTTT
3661 CAGACTATAA CTTCAGCCAT CGAAGATCAA ACTGTACACC CCAAATGCTT TTTCTTGGAT
3721 GGTCCAGGTG GTAGTGGAAA AACATATCTG TATAAAGTTT TAACACATTA TATTAGAGGT
3781 CGTGGTGGTA CTGTTTTACC CACAGCATCT ACAGGAATTG CTGCAAATTT ACTTCTTGGT
3841 GGAAGAACCT TTCATTCCCA ATATAAATTA CCAATTCCAT TAAATGAAAC TTCAATTTCT
3901 AGACTCGATA TAAAGAGTGA AGTTGCTAAA ACCATTAAAA AGGCCCAACT TCTCATTATT
3961 GATGAATGCA CCATGGCATC CAGTCATGCT ATAAACGCCA TAGATAGATT ACTAAGAGAA
4021 ATTATGAATT TGAATGTTGC ATTTGGTGGG AAAGTTCTCC TTCTCGGAGG GGATTTTCGA
4081 CAATGTCTCA GTATTGTACC ACATGCTATG CGATCGGCCA TAGTACAAAC GAGTTTAAAG
4141 TACTGTAATG TTTGGGGATG TTTCAGAAAG TTGTCTCTTA AAACAAATAT GAGATCAGAG
4201 GATTCTGCTT ATAGTGAATG GTTAGTAAAA CTTGGAGATG GCAAACTTGA TAGCAGTTTT
4261 CATTTAGGAA TGGATATTAT TGAAATCCCC CATGAAATGA TTTGTAACGG ATCTATTATT
4321 GAAGCTACCT TTGGAAATAG TATATCTATA GATAATATTA AAAATATATC TAAACGTGCA
4381 ATTCTTTGTC CAAAAAATGA GCATGTTCAA AAATTAAATG AAGAAATTTT GGATATACTT
4441 GATGGAGATT TTCACACATA TTTGAGTGAT GATTCCATTG ATTCAACAGA TGATGCTGAA
4501 AAGGAAAATT TTCCCATCGA ATTTCTTAAT AGTATTACTC CTTCGGGAAT GCCGTGTCAT
4561 AAATTAAAAT TGAAAGTGGG TGCAATCATC ATGCTATTGA GAAATCTTAA TAGTAAATGG
4621 GGTCTTTGTA ATGGTACTAG ATTTATTATC AAAAGATTAC GACCTAACAT TATCGAAGCT
4681 GAAGTATTAA CAGGATCTGC AGAGGGAGAG GTTGTTCTGA TTCCAAGAAT TGATTTGTCC
4741 CCATCTGACA CTGGCCTCCC ATTTAAATTA ATTCGAAGAC AGTTTCCCGT GATGCCAGCA
4801 TTTGCGATGA CTATTAATAA ATCACAAGGA CAAACTCTAG ACAGAGTAGG AATATTCCTA
4861 CCTGAACCCG TTTTCGCACA TGGTCAGTTA TATGTTGCTT TCTCTCGAGT TCGAAGAGCA
4921 TGTGACGTTA AAGTTAAAGT TGTAAATACT TCATCACAAG GGAAATTAGT CAAGCACTCT
4981 GAAAGTGTTT TTACTCTTAA TGTGGTATAC AGGGAGATAT TAGAATAAGT TTAATCACTT
5041 TATCAGTCAT TGTTTGCATC AATGTTGTTT TTATATCATG TTTTTGTTGT TTTTATATCA
5101 TGTCTTTGTT GTTGTTATAT CATGTTGTTA TTGTTTATTT ATTAATAAAT TTATGTATTA
5161 TTTTCATATA CATTTTACTC ATTTCCTTTC ATCTCTCACA CTTCTATTAT AGAGAAAGGG
5221 CAAATAGCAA TATTAAAATA TTTCCTCTAA TTAATTCCCT TTCAATGTGC ACGAATTTCG
5281 TGCACCGGGC CACTAG(配列番号18061)を含む核酸配列を含んでいる。
1 MSKEQLLIQR SSAAERCRRY RQKMSAEQRA SDLERRRRLQ QNVSEEQLLE KRRSEAEKQR
61 RHRQKMSKDQ RAFEVERRRW RRQNMSREQS STSTTNTGRN CLLSKNGVHE DAILEHSCGG
121 MTVRCEFCLS LNFSDEKPSD GKFTRCCSKG KVCPNDIHFP DYPAYLKRLM TNEDSDSKNF
181 MENIRSINSS FAFASMGANI ASPSGYGPYC FRIHGQVYHR TGTLHPSDGV SRKFAQLYIL
241 DTAEATSKRL AMPENQGCSE RLMININNLM HEINELTKSY KMLHEVEKEA QSEAAAKGIA
301 PTEVTMAIKY DRNSDPGRYN SPRVTEVAVI FRNEDGEPPF ERDLLIHCKP DPNNPNATKM
361 KQISILFPTL DAMTYPILFP HGEKGWGTDI ALRLRDNSVI DNNTRQNVRT RVTQMQYYGF
421 HLSVRDTFNP ILNAGKLTQQ FIVDSYSKME ANRINFIKAN QSKLRVEKYS GLMDYLKSRS
481 ENDNVPIGKM IILPSSFEGS PRNMQQRYQD AMAIVTKYGK PDLFITMTCN PKWADITNNL
541 QRWQKVENRP DLVARVFNIK LNALLNDICK FHLFGKVIAK IHVIEFQKRG LPHAHILLIL
601 DSESKLRSED DIDRIVKAEI PDEDQCPRLF QIVKSNMVHG PCGIQNPNSP CMENGKCSKG
661 YPKEFQNATI GNIDGYPKYK RRSGSTMSIG NKVVDNTWIV PYNPYLCLKY NCHINVEVCA
721 SIKSVKYLFK YIYKGHDCAN IQISEKNIIN HDEVQDFIDS RYVSAPEAVW RLFAMRMHDQ
781 SHAITRLAIH LPNDQNLYFH TDDFAEVLDR AKRHNSTLMA WFLLNREDSD ARNYYYWEIP
841 QHYVFNNSLW TKRRKGGNKV LGRLFTVSFR EPERYYLRLL LLHVKGAISF EDLRTVGGVT
901 YDTFHEAAKH RGLLLDDTIW KDTIDDAIIL NMPKQLRQLF AYICVFGCPS AADKLWDENK
961 SHFIEDFCWK LHRREGACVN CEMHALNEIQ EVFTLHGMKC SHFKLPDYPL LMNANTCDQL
1021 YEQQQAEVLI NSLNDEQLAA FQTITSAIED QTVHPKCFFL DGPGGSGKTY LYKVLTHYIR
1081 GRGGTVLPTA STGIAANLLL GGRTFHSQYK LPIPLNETSI SRLDIKSEVA KTIKKAQLLI
1141 IDECTMASSH AINAIDRLLR EIMNLNVAFG GKVLLLGGDF RQCLSIVPHA MRSAIVQTSL
1201 KYCNVWGCFR KLSLKTNMRS EDSAYSEWLV KLGDGKLDSS FHLGMDIIEI PHEMICNGSI
1261 IEATFGNSIS IDNIKNISKR AILCPKNEHV QKLNEEILDI LDGDFHTYLS DDSIDSTDDA
1321 EKENFPIEFL NSITPSGMPC HKLKLKVGAI IMLLRNLNSK WGLCNGTRFI IKRLRPNIIE
1381 AEVLTGSAEG EVVLIPRIDL SPSDTGLPFK LIRRQFPVMP AFAMTINKSQ GQTLDRVGIF
1441 LPEPVFAHGQ LYVAFSRVRR ACDVKVKVVN TSSQGKLVKH SESVFTLNVV YREILE(配列番号14501)を含むアミノ酸配列を含んでいる。
1 MEEVCDSSAA ASSTVQNQPQ DQEHPWPYLR EFFSLSGVNK DSFKMKCVLC LPLNKEISAF
61 KSSPSNLRKH IERMHPNYLK NYSKLTAQKR KIGTSTHASS SKQLKVDSVF PVKHVSPVTV
121 NKAILRYIIQ GLHPFSTVDL PSFKELISTL QPGISVITRP TLRSKIAEAA LIMKQKVTAA
181 MSEVEWIATT TDCWTARRKS FIGVTAHWIN PGSLERHSAA LACKRLMGSH TFEVLASAMN
241 DIHSEYEIRD KVVCTTTDSG SNFMKAFRVF GVENNDIETE ARRCESDDTD SEGCGEGSDG
301 VEFQDASRVL DQDDGFEFQL PKHQKCACHL LNLVSSVDAQ KALSNEHYKK LYRSVFGKCQ
361 ALWNKSSRSA LAAEAVESES RLQLLRPNQT RWNSTFMAVD RILQICKEAG EGALRNICTS
421 LEVPMFNPAE MLFLTEWANT MRPVAKVLDI LQAETNTQLG WLLPSVHQLS LKLQRLHHSL
481 RYCDPLVDAL QQGIQTRFKH MFEDPEIIAA AILLPKFRTS WTNDETIIKR GMDYIRVHLE
541 PLDHKKELAN SSSDDEDFFA SLKPTTHEAS KELDGYLACV SDTRESLLTF PAICSLSIKT
601 NTPLPASAAC ERLFSTAGLL FSPKRARLDT NNFENQLLLK LNLRFYNFE(配列番号14502)を含むアミノ酸配列を含んでいる。
1 CAGAGGTGTA AAGTACTTGA GTAATTTTAC TTGATTACTG TACTTAAGTA TTATTTTTGG
61 GGATTTTTAC TTTACTTGAG TACAATTAAA AATCAATACT TTTACTTTTA CTTAATTACA
121 TTTTTTTAGA AAAAAAAGTA CTTTTTACTC CTTACAATTT TATTTACAGT CAAAAAGTAC
181 TTATTTTTTG GAGATCACTT CATTCTATTT TCCCTTGCTA TTACCAAACC AATTGAATTG
241 CGCTGATGCC CAGTTTAATT TAAATGTTAT TTATTCTGCC TATGAAAATC GTTTTCACAT
301 TATATGAAAT TGGTCAGACA TGTTCATTGG TCCTTTGGAA GTGACGTCAT GTCACATCTA
361 TTACCACAAT GCACAGCACC TTGACCTGGA AATTAGGGAA ATTATAACAG TCAATCAGTG
421 GAAGAAAATG GAGGAAGTAT GTGATTCATC AGCAGCTGCG AGCAGCACAG TCCAAAATCA
481 GCCACAGGAT CAAGAGCACC CGTGGCCGTA TCTTCGCGAA TTCTTTTCTT TAAGTGGTGT
541 AAATAAAGAT TCATTCAAGA TGAAATGTGT CCTCTGTCTC CCGCTTAATA AAGAAATATC
601 GGCCTTCAAA AGTTCGCCAT CAAACCTAAG GAAGCATATT GAGGTAAGTA CATTAAGTAT
661 TTTGTTTTAC TGATAGTTTT TTTTTTTTTT TTTTTTTTTT TTTTTGGGTG TGCATGTTTT
721 GACGTTGATG GCGCGCCTTT TATATGTGTA GTAGGCCTAT TTTCACTAAT GCATGCGATT
781 GACAATATAA GGCTCACGTA ATAAAATGCT AAAATGCATT TGTAATTGGT AACGTTAGGT
841 CCACGGGAAA TTTGGCGCCT ATTGCAGCTT TGAATAATCA TTATCATTCC GTGCTCTCAT
901 TGTGTTTGAA TTCATGCAAA ACACAAGAAA ACCAAGCGAG AAATTTTTTT CCAAACATGT
961 TGTATTGTCA AAACGGTAAC ACTTTACAAT GAGGTTGATT AGTTCATGTA TTAACTAACA
1021 TTAAATAACC ATGAGCAATA CATTTGTTAC TGTATCTGTT AATCTTTGTT AACGTTAGTT
1081 AATAGAAATA CAGATGTTCA TTGTTTGTTC ATGTTAGTTC ACAGTGCATT AACTAATGTT
1141 AACAAGATAT AAAGTATTAG TAAATGTTGA AATTAACATG TATACGTGCA GTTCATTATT
1201 AGTTCATGTT AACTAATGTA GTTAACTAAC GAACCTTATT GTAAAAGTGT TACCATCAAA
1261 ACTAATGTAA TGAAATCAAT TCACCCTGTC ATGTCAGCCT TACAGTCCTG TGTTTTTGTC
1321 AATATAATCA GAAATAAAAT TAATGTTTGA TTGTCACTAA ATGCTACTGT ATTTCTAAAA
1381 TCAACAAGTA TTTAACATTA TAAAGTGTGC AATTGGCTGC AAATGTCAGT TTTATTAAAG
1441 GGTTAGTTCA CCCAAAAATG AAAATAATGT CATTAATGAC TCGCCCTCAT GTCGTTCCAA
1501 GCCCGTAAGA CCTCCGTTCA TCTTCAGAAC ACAGTTTAAG ATATTTTAGA TTTAGTCCGA
1561 GAGCTTTCTG TGCCTCCATT GAGAATGTAT GTACGGTATA CTGTCCATGT CCAGAAAGGT
1621 AATAAAAACA TCAAAGTAGT CCATGTGACA TCAGTGGGTT AGTTAGAATT TTTTGAAGCA
1681 TCGAATACAT TTTGGTCCAA AAATAACAAA ACCTACGACT TTATTCGGCA TTGTATTCTC
1741 TTCCGGGTCT GTTGTCAATC CGCGTTCACG ACTTCGCAGT GACGCTACAA TGCTGAATAA
1801 AGTCGTAGGT TTTGTTATTT TTGGACCAAA ATGTATTTTC GATGCTTCAA ATAATTCTAC
1861 CTAACCCACT GATGTCACAT GGACTACTTT GATGTTTTTA TTACCTTTCT GGACATGGAC
1921 AGTATACCGT ACATACATTT TCAGTGGAGG GACAGAAAGC TCTCGGACTA AATCTAAAAT
1981 ATCTTAAACT GTGTTCCGAA GATGAACGGA GGTGTTACGG GCTTGGAACG ACATGAGGGT
2041 GAGTCATTAA TGACATCTTT TCATTTTTGG GTGAACTAAC CCTTTAATGC TGTAATCAGA
2101 GAGTGTATGT GTAATTGTTA CATTTATTGC ATACAATATA AATATTTATT TGTTGTTTTT
2161 ACAGAGAATG CACCCAAATT ACCTCAAAAA CTACTCTAAA TTGACAGCAC AGAAGAGAAA
2221 GATCGGGACC TCCACCCATG CTTCCAGCAG TAAGCAACTG AAAGTTGACT CAGTTTTCCC
2281 AGTCAAACAT GTGTCTCCAG TCACTGTGAA CAAAGCTATA TTAAGGTACA TCATTCAAGG
2341 ACTTCATCCT TTCAGCACTG TTGATCTGCC ATCATTTAAA GAGCTGATTA GTACACTGCA
2401 GCCTGGCATT TCTGTCATTA CAAGGCCTAC TTTACGCTCC AAGATAGCTG AAGCTGCTCT
2461 GATCATGAAA CAGAAAGTGA CTGCTGCCAT GAGTGAAGTT GAATGGATTG CAACCACAAC
2521 GGATTGTTGG ACTGCACGTA GAAAGTCATT CATTGGTGTA ACTGCTCACT GGATCAACCC
2581 TGGAAGTCTT GAAAGACATT CCGCTGCACT TGCCTGCAAA AGATTAATGG GCTCTCATAC
2641 TTTTGAGGTA CTGGCCAGTG CCATGAATGA TATCCACTCA GAGTATGAAA TACGTGACAA
2701 GGTTGTTTGC ACAACCACAG ACAGTGGTTC CAACTTTATG AAGGCTTTCA GAGTTTTTGG
2761 TGTGGAAAAC AATGATATCG AGACTGAGGC AAGAAGGTGT GAAAGTGATG ACACTGATTC
2821 TGAAGGCTGT GGTGAGGGAA GTGATGGTGT GGAATTCCAA GATGCCTCAC GAGTCCTGGA
2881 CCAAGACGAT GGCTTCGAAT TCCAGCTACC AAAACATCAA AAGTGTGCCT GTCACTTACT
2941 TAACCTAGTC TCAAGCGTTG ATGCCCAAAA AGCTCTCTCA AATGAACACT ACAAGAAACT
3001 CTACAGATCT GTCTTTGGCA AATGCCAAGC TTTATGGAAT AAAAGCAGCC GATCGGCTCT
3061 AGCAGCTGAA GCTGTTGAAT CAGAAAGCCG GCTTCAGCTT TTAAGGCCAA ACCAAACGCG
3121 GTGGAATTCA ACTTTTATGG CTGTTGACAG AATTCTTCAA ATTTGCAAAG AAGCAGGAGA
3181 AGGCGCACTT CGGAATATAT GCACCTCTCT TGAGGTTCCA ATGTAAGTGT TTTTCCCCTC
3241 TATCGATGTA AACAAATGTG GGTTGTTTTT GTTTAATACT CTTTGATTAT GCTGATTTCT
3301 CCTGTAGGTT TAATCCAGCA GAAATGCTGT TCTTGACAGA GTGGGCCAAC ACAATGCGTC
3361 CAGTTGCAAA AGTACTCGAC ATCTTGCAAG CGGAAACGAA TACACAGCTG GGGTGGCTGC
3421 TGCCTAGTGT CCATCAGTTA AGCTTGAAAC TTCAGCGACT CCACCATTCT CTCAGGTACT
3481 GTGACCCACT TGTGGATGCC CTACAACAAG GAATCCAAAC ACGATTCAAG CATATGTTTG
3541 AAGATCCTGA GATCATAGCA GCTGCCATCC TTCTCCCTAA ATTTCGGACC TCTTGGACAA
3601 ATGATGAAAC CATCATAAAA CGAGGTAAAT GAATGCAAGC AACATACACT TGACGAATTC
3661 TAATCTGGGC AACCTTTGAG CCATACCAAA ATTATTCTTT TATTTATTTA TTTTTGCACT
3721 TTTTAGGAAT GTTATATCCC ATCTTTGGCT GTGATCTCAA TATGAATATT GATGTAAAGT
3781 ATTCTTGCAG CAGGTTGTAG TTATCCCTCA GTGTTTCTTG AAACCAAACT CATATGTATC
3841 ATATGTGGTT TGGAAATGCA GTTAGATTTT ATGCTAAAAT AAGGGATTTG CATGATTTTA
3901 GATGTAGATG ACTGCACGTA AATGTAGTTA ATGACAAAAT CCATAAAATT TGTTCCCAGT
3961 CAGAAGCCCC TCAACCAAAC TTTTCTTTGT GTCTGCTCAC TGTGCTTGTA GGCATGGACT
4021 ACATCAGAGT GCATCTGGAG CCTTTGGACC ACAAGAAGGA ATTGGCCAAC AGTTCATCTG
4081 ATGATGAAGA TTTTTTCGCT TCTTTGAAAC CGACAACACA TGAAGCCAGC AAAGAGTTGG
4141 ATGGATATCT GGCCTGTGTT TCAGACACCA GGGAGTCTCT GCTCACGTTT CCTGCTATTT
4201 GCAGCCTCTC TATCAAGACT AATACACCTC TTCCCGCATC GGCTGCCTGT GAGAGGCTTT
4261 TCAGCACTGC AGGATTGCTT TTCAGCCCCA AAAGAGCTAG GCTTGACACT AACAATTTTG
4321 AGAATCAGCT TCTACTGAAG TTAAATCTGA GGTTTTACAA CTTTGAGTAG CGTGTACTGG
4381 CATTAGATTG TCTGTCTTAT AGTTTGATAA TTAAATACAA ACAGTTCTAA AGCAGGATAA
4441 AACCTTGTAT GCATTTCATT TAATGTTTTT TGAGATTAAA AGCTTAAACA AGAATCTCTA
4501 GTTTTCTTTC TTGCTTTTAC TTTTACTTCC TTAATACTCA AGTACAATTT TAATGGAGTA
4561 CTTTTTTACT TTTACTCAAG TAAGATTCTA GCCAGATACT TTTACTTTTA ATTGAGTAAA
4621 ATTTTCCCTA AGTACTTGTA CTTTCACTTG AGTAAAATTT TTGAGTACTT TTTACACCTC
4681 TG(配列番号18062)を含む核酸配列によってコードされている。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)の30位、165位、282位、538位のうちの1つ以上にアミノ酸置換を有するアミノ酸配列を含むか、このアミノ酸配列からなるpiggyBacトランスポザーゼ酵素またはpiggyBac様トランスポザーゼ酵素である。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPKEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14484)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRHRQTKT AAENSSAETS
181 FYMQETTLCE LKALIALLYL AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLQNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ CCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FDVVNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELSANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRANKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KHSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14504)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRHRQTKT AAENSSAETS
181 FYMQETTLCE LKALIALLYL AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLQNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ CCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVVNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14505)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 atggcaccca aaaagaaacg taaagtgatg gacattgaaa gacaggaaga aagaatcagg
61 gcgatgctcg aagaagaact gagcgactac tccgacgaat cgtcatcaga ggatgaaacc
121 gaccactgta gcgagcatga ggttaactac gacaccgagg aggagagaat cgactctgtg
181 gatgtgccct ccaactcacg ccaagaagag gccaatgcaa ttatcgcaaa cgaatcggac
241 agcgatccag acgatgatct gccactgtcc ctcgtgcgcc agcgggccag cgcttcgaga
301 caagtgtcag gtccattcta cacttcgaag gacggcacta agtggtacaa gaattgccag
361 cgacctaacg tcagactccg ctccgagaat atcgtgaccg aacaggctca ggtcaagaat
421 atcgcccgcg acgcctcgac tgagtacgag tgttggaata tcttcgtgac ttcggacatg
481 ctgcaagaaa ttctgacgca caccaacagc tcgattaggc atcgccagac caagactgca
541 gcggagaact catcggccga aacctccttc tatatgcaag agactactct gtgcgaactg
601 aaggcgctga ttgcactgct gtacttggcc ggcctcatca aatcaaatag gcagagcctc
661 aaagatctct ggagaacgga tggaactgga gtggatatct ttcggacgac tatgagcttg
721 cagcggttcc agtttctgca aaacaatatc agattcgacg acaagtccac ccgggacgaa
781 aggaaacaga ctgacaacat ggctgcgttc cggtcaatat tcgatcagtt tgtgcagtgc
841 tgccaaaacg cttatagccc atcggaattc ctgaccatcg acgaaatgct tctctccttc
901 cgggggcgct gcctgttccg agtgtacatc ccgaacaagc cggctaaata cggaatcaaa
961 atcctggccc tggtggacgc caagaatttc tacgtcgtga atctcgaagt gtacgcagga
1021 aagcaaccgt cgggaccgta cgctgtttcg aaccgcccgt ttgaagtcgt cgagcggctt
1081 attcagccgg tggccagatc ccaccgcaat gttaccttcg acaattggtt caccggctac
1141 gagctgatgc ttcaccttct gaacgagtac cggctcacta gcgtggggac tgtcaggaag
1201 aacaagcggc agatcccaga atccttcatc cgcaccgacc gccagcctaa ctcgtccgtg
1261 ttcggatttc aaaaggatat cacgcttgtc tcgtacgccc ccaagaaaaa caaggtcgtg
1321 gtcgtgatga gcaccatgca tcacgacaac agcatcgacg agtcaaccgg agaaaagcaa
1381 aagcccgaga tgatcacctt ctacaattca actaaggccg gcgtcgacgt cgtggatgaa
1441 ctgtgcgcga actataacgt gtcccggaac tctaagcggt ggcctatgac tctcttctac
1501 ggagtgctga atatggccgc aatcaacgcg tgcatcatct accgcaccaa caagaacgtg
1561 accatcaagc gcaccgagtt catcagatcg ctgggtttga gcatgatcta cgagcacctc
1621 cattcacgga acaagaagaa gaatatccct acttacctga ggcagcgtat cgagaagcag
1681 ttgggagaac caagcccgcg ccacgtgaac gtgccggggc gctacgtgcg gtgccaagat
1741 tgcccgtaca aaaaggaccg caaaaccaaa agatcgtgta acgcgtgcgc caaacctatc
1801 tgcatggagc atgccaaatt tctgtgtgaa aattgtgctg aactcgattc ctccctg(配列番号14629)を含むポリヌクレオチド配列によってコードされる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQMSGPHYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRWRQTKT AAENSSASTS
181 FYMQETTLCE LKALIGLLYI AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLQNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ SCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVKNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSHL(配列番号14576)と少なくとも90%一致する配列を含んでいる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRWRQTKT AAENSSAETS
181 FYMQETTLCE LKALIGLLYI AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLLNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ SCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVHNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YEVMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAHLDS(配列番号14630)の配列を含んでいる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRWRQTKT AAENSSASTS
181 FYMQETTLCE LKALIGLLYI AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLLNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ SCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVKNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIAM QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14631)の配列を含んでいる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRWRQTKT AAENSSAETS
181 FYMQETTLCE LKALIGLLYI AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLLNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ SCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVKNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKTQIPENF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELQANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14632)の配列を含んでいる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRWRQTKT AAENSSAETS
181 FYMQETTLCE LKALIGLLYI AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLQNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ SCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVKNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14633)の配列を含んでいる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRHRQTKT AAENSSAETS
181 FYMQETTLCE LKALIALLYL AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFQFLQNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ CCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN DYVVNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSSRHV NVKGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14634)の配列を含んでいる。
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRHRQTKT AAENSSAETS
181 FYMQETTLCE LKALIALLYL AGLIKSNRQS LKDLWRKDGT GVDIFRTTMS LQRFQFLLNN
241 IRFDDISTRD ERKQTDNMAA FRSIFDQFVQ CCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVVNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKKWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMMYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPVPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14606)の配列を含んでいる。
いくつかの実施態様では、組み込み不足のpiggyBacトランスポザーゼまたはpiggyBac 様トランスポザーゼは、
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRHRQTKT AAENSSAETS
181 FYMQETTLCE LKALIGLLYL AGLIKSNRQS LKDLWRTDGT GVDIFRTTMS LQRFYFLQNN
241 IRFDDKSTLD ERKQTDNMAA FRSIFDQFVQ SCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN FYVVNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YELMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKRWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIYEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NYPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 VNCAELDSSL(配列番号14607)の配列を含んでいる。
いくつかの実施態様では、組み込み不足のpiggyBacトランスポザーゼまたはpiggyBac 様トランスポザーゼは、
1 MDIERQEERI RAMLEEELSD YSDESSSEDE TDHCSEHEVN YDTEEERIDS VDVPSNSRQE
61 EANAIIANES DSDPDDDLPL SLVRQRASAS RQVSGPFYTS KDGTKWYKNC QRPNVRLRSE
121 NIVTEQAQVK NIARDASTEY ECWNIFVTSD MLQEILTHTN SSIRHRQTKT AAENSSAETS
181 FYMQETTLCE LKALIALLYL AGLIKSNRQS LKDLWRKDGT GVDIFRTTMS LQRFQFLLNN
241 IRFDDKSTRD ERKQTDNMAA FRSIFDQFVQ CCQNAYSPSE FLTIDEMLLS FRGRCLFRVY
301 IPNKPAKYGI KILALVDAKN DYVVNLEVYA GKQPSGPYAV SNRPFEVVER LIQPVARSHR
361 NVTFDNWFTG YECMLHLLNE YRLTSVGTVR KNKRQIPESF IRTDRQPNSS VFGFQKDITL
421 VSYAPKKNKV VVVMSTMHHD NSIDESTGEK QKPEMITFYN STKAGVDVVD ELCANYNVSR
481 NSKKWPMTLF YGVLNMAAIN ACIIYRTNKN VTIKRTEFIR SLGLSMIKEH LHSRNKKKNI
541 PTYLRQRIEK QLGEPSPRHV NVPGRYVRCQ DCPYKKDRKT KRSCNACAKP ICMEHAKFLC
601 ENCAELDSSL(配列番号14608)の配列を含んでいる。
いくつかの実施態様では、組み込み不足のトランスポザーゼは、配列番号14608と少なくとも90%一致する配列を含んでいる。
1 ttatcccggc gagcatgagg cagggtatct cataccctgg taaaatttta aagttgtgta
61 ttttataaaa ttttcgtctg acaacactag cgcgctcagt agctggaggc aggagcgtgc
121 gggaggggat agtggcgtga tcgcagtgtg gcacgggaca ccggcgagat attcgtgtgc
181 aaacctgttt cgggtatgtt ataccctgcc tcattgttga cgtatttttt ttatgtaatt
241 tttccgatta ttaatttcaa ctgttttatt ggtattttta tgttatccat tgttcttttt
301 ttatgattta ctgtatcggt tgtctttcgt tcctttagtt gagttttttt ttattatttt
361 cagtttttga tcaaa(配列番号14506)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tcatattttt agtttaaaaa aataattata tgttttataa tgaaaagaat ctcattatct
61 ttcagtatta ggttgattta tattccaaag aataatattt ttgttaaatt gttgattttt
121 gtaaacctct aaatgtttgt tgctaaaatt actgtgttta agaaaaagat taataaataa
181 taataatttc ataattaaaa acttctttca ttgaatgcca ttaaataaac cattatttta
241 caaaataaga tcaacataat tgagtaaata ataataagaa caatattata gtacaacaaa
301 atatgggtat gtcataccct gccacattct tgatgtaact ttttttcacc tcatgctcgc
361 cgggttat(配列番号14507)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 ttatcccggc gagcatgagg cagggtatct cataccctgg taaaatttta aagttgtgta
61 ttttataaaa ttttcgtctg acaacactag cgcgctcagt agctggaggc aggagcgtgc
121 gggaggggat agtggcgtga tcgcagtgtg gcacgggaca ccggcgagat attcgtgtgc
181 aaacctgttt cgggtatgtt ataccctgcc tcat(配列番号14508)の配列を含んでいる。
いくつかの実施態様では、piggyBac(商標)(PB)トランスポゾンまたはpiggyBac様トランスポゾンは、
1 taaataataa taatttcata attaaaaact tctttcattg aatgccatta aataaaccat
61 tattttacaa aataagatca acataattga gtaaataata ataagaacaa tattatagta
121 caacaaaata tgggtatgtc ataccctgcc acattcttga tgtaactttt tttcacctca
181 tgctcgccgg gttat(配列番号14509)の配列を含んでいる。
1 ttaacccggc gagcatgagg cagggtatct cataccctgg taaaatttta aagttgtgta
61 ttttataaaa ttttcgtctg acaacactag cgcgctcagt agctggaggc aggagcgtgc
121 gggaggggat agtggcgtga tcgcagtgtg gcacgggaca ccggcgagat attcgtgtgc
181 aaacctgttt cgggtatgtt ataccctgcc tcattgttga cgtatttttt ttatgtaatt
241 tttccgatta ttaatttcaa ctgttttatt ggtattttta tgttatccat tgttcttttt
301 ttatgattta ctgtatcggt tgtctttcgt tcctttagtt gagttttttt ttattatttt
361 cagtttttga tcaaa(配列番号14515)の配列を含んでいる。
1 tcatattttt agtttaaaaa aataattata tgttttataa tgaaaagaat ctcattatct
61 ttcagtatta ggttgattta tattccaaag aataatattt ttgttaaatt gttgattttt
121 gtaaacctct aaatgtttgt tgctaaaatt actgtgttta agaaaaagat taataaataa
181 taataatttc ataattaaaa acttctttca ttgaatgcca ttaaataatt cattatttta
241 caaaataaga tcaacataat tgagtaaata ataataagaa caatattata gtacaacaaa
301 atatgggtat gtcataccct tttttttttt tttttttttt ttttttcggg tagagggccg
361 aacctcctac gaggtccccg cgcaaaaggg gcgcgcgggg tatgtgagac tcaacgatct
421 gcatggtgtt gtgagcagac cgcgggccca aggattttag agcccaccca ctaaacgact
481 cctctgcact cttacacccg acgtccgatc ccctccgagg tcagaacccg gatgaggtag
541 gggggctacc gcggtcaaca ctacaaccag acggcgcggc tcaccccaag gacgcccagc
601 cgacggagcc ttcgaggcga atcgaaggct ctgaaacgtc ggccgtctcg gtacggcagc
661 ccgtcgggcc gcccagacgg tgccgctggt gtcccggaat accccgctgg accagaacca
721 gcctgccggg tcgggacgcg atacaccgtc gaccggtcgc tctaatcact ccacggcagc
781 gcgctagagt gctggta(配列番号14516)の配列を含んでいる。
1 cccggcgagc atgaggcagg gtatctcata ccctggtaaa attttaaagt tgtgtatttt
61 ataaaatttt cgtctgacaa cactagcgcg ctcagtagct ggaggcagga gcgtgcggga
121 ggggatagtg gcgtgatcgc agtgtggcac gggacaccgg cgagatattc gtgtgcaaac
181 ctgtttcggg tatgttatac cctgcctcat tgttgacgta t(配列番号14577)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tttaagaaaa agattaataa ataataataa tttcataatt aaaaacttct ttcattgaat
61 gccattaaat aaaccattat tttacaaaat aagatcaaca taattgagta aataataata
121 agaacaatat tatagtacaa caaaatatgg gtatgtcata ccctgccaca ttcttgatgt
181 aacttttttt cacctcatgc tcgccggg(配列番号14578)の配列を含んでいる。
いくつかの実施態様では、トランスポゾンは、配列番号14577からの少なくとも16個の連続した塩基と、配列番号14578からの少なくとも16個の連続した塩基と、CCCGGCGAGCATGAGG(配列番号14510)と少なくとも87%一致する逆方向末端反復を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 cccggcgagc atgaggcagg gtatctcata ccctggtaaa attttaaagt tgtgtatttt
61 ataaaatttt cgtctgacaa cactagcgcg ctcagtagct ggaggcagga gcgtgcggga
121 ggggatagtg gcgtgatcgc agtgtggcac gggacaccgg cgagatattc gtgtgcaaac
181 ctgtttcggg tatgttatac cctgcctcat tgttgacgta ttttttttat gtaatttttc
241 cgattattaa tttcaactgt tttattggta tttttatgtt atccattgtt ctttttttat
301 gatttactgt atcggttgtc tttcgttcct ttagttgagt ttttttttat tattttcagt
361 ttttgatcaa a(配列番号14595)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tcatattttt agtttaaaaa aataattata tgttttataa tgaaaagaat ctcattatct
61 ttcagtatta ggttgattta tattccaaag aataatattt ttgttaaatt gttgattttt
121 gtaaacctct aaatgtttgt tgctaaaatt actgtgttta agaaaaagat taataaataa
181 taataatttc ataattaaaa acttctttca ttgaatgcca ttaaataaac cattatttta
241 caaaataaga tcaacataat tgagtaaata ataataagaa caatattata gtacaacaaa
301 atatgggtat gtcataccct gccacattct tgatgtaact ttttttcacc tcatgctcgc
361 cggg(配列番号14596)の配列を含んでいる。
1 cccggcgagc atgaggcagg gtatctcata ccctggtaaa attttaaagt tgtgtatttt
61 ataaaatttt cgtctgacaa cactagcgcg ctcagtagct ggaggcagga gcgtgcggga
121 ggggatagtg gcgtgatcgc agtgtggcac gggacaccgg cgagatattc gtgtgcaaac
181 ctgtttcggg tatgttatac cctgcctcat tgttgacgta ttttttttat gtaatttttc
241 cgattattaa tttcaactgt tttattggta tttttatgtt atccattgtt ctttttttat
301 g (配列番号14597)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 cagggtatct cataccctgg taaaatttta aagttgtgta ttttataaaa ttttcgtctg
61 acaacactag cgcgctcagt agctggaggc aggagcgtgc gggaggggat agtggcgtga
121 tcgcagtgtg gcacgggaca ccggcgagat attcgtgtgc aaacctgttt cgggtatgtt
181 ataccctgcc tcattgttga cgtatttttt ttatgtaatt tttccgatta ttaatttcaa
241 ctgttttatt ggtattttta tgttatccat tgttcttttt ttatg(配列番号14598)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 cagggtatct cataccctgg taaaatttta aagttgtgta ttttataaaa ttttcgtctg
61 acaacactag cgcgctcagt agctggaggc aggagcgtgc gggaggggat agtggcgtga
121 tcgcagtgtg gcacgggaca ccggcgagat attcgtgtgc aaacctgttt cgggtatgtt
181 ataccctgcc tcattgttga cgtat(配列番号14599)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンの5'末端は、配列番号14577、配列番号14595、配列番号14597~14599いずれかの配列を含んでいる。いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンの5'末端の前に5'標的配列がある。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tcatattttt agtttaaaaa aataattata tgttttataa tgaaaagaat ctcattatct
61 ttcagtatta ggttgattta tattccaaag aataatattt ttgttaaatt gttgattttt
121 gtaaacctct aaatgtttgt tgctaaaatt actgtgttta agaaaaagat taataaataa
181 taataatttc ataattaaaa acttctttca ttgaatgcca ttaaataaac cattatttta
241 caaaataaga tcaacataat tgagtaaata ataataagaa caatattata gtacaacaaa
301 atatgggtat gtcataccct gccacattct tgatgtaact ttttttcacc tcatgctcgc
361 cggg(配列番号14600)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tttaagaaaa agattaataa ataataataa tttcataatt aaaaacttct ttcattgaat
61 gccattaaat aaaccattat tttacaaaat aagatcaaca taattgagta aataataata
121 agaacaatat tatagtacaa caaaatatgg gtatgtcata ccctgccaca ttcttgatgt
181 aacttttttt ca(配列番号14601)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 cccggcgagc atgaggcagg gtatctcata ccctggtaaa attttaaagt tgtgtatttt
61 ataaaatttt cgtctgacaa cactagcgcg ctcagtagct ggaggcagga gcgtgcggga
121 ggggatagtg gcgtgatcgc agtgtggcac gggacaccgg cgagatattc gtgtgcaaac
181 ctgtttcggg tatgttatac cctgcctcat tgttgacgta ttttttttat gtaatttttc
241 cgattattaa tttcaactgt tttattggta tttttatgtt atccattgtt ctttttttat
301 gatttactgt atcggttgtc tttcgttcct ttagttgagt ttttttttat tattttcagt
361 ttttgatcaa a(配列番号14602)の配列を含んでいる。
GGGTAT(配列番号14616)、ATACCCTGCC(配列番号14617)、TAAAATTTTA(配列番号14618)、ATTTTATAAAAT(配列番号14619)、TCATACCCTG(配列番号14620)、TAA
ATAATAATAA(配列番号14621)から選択された1つ、または2つ、または3つ、または4つ、または5つ、または6つ、または7つの配列を含む5'末端を含んでいる。いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、配列番号14617、配列番号14620、配列番号14621から選択された1つ、または2つ、または3つの配列を含む3'末端を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFSAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHY(配列番号14517)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MAKRFYSAEE AAAHCMAPSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWNTTT VLSIPVFSAT MSRNRYQLLL RFLHFNNNAT AVPPDQPDHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLR FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRTR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT SAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMLP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHY(配列番号14518)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 MAKRFYSAEE AAAHCSASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLTRG ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SIESYWDTTT VLSIPVFGAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFANVY TPCQNICIDE SLMLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSTGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPD SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCRKPCF EIYHTQLHY(配列番号14572)と少なくとも90%一致する配列を含んでいる。
1 MAKRFYSAEE AAAHCSASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLTRG ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SIESYWDTTT VLSIPVFGAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFANVY TPCQNICIDE SLMLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSTGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPD SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCRKPCF EIYHTQLHY(配列番号14572)の配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLTRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFSAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCRKPCF EIYHTQLHY(配列番号14624)の配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLKIPVFSAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHY(配列番号14625)の配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EQTSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLTRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SIESYWDTTT VLSIPVFGAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFANVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRKPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCRKPCF EIYHTQLHY(配列番号14627)の配列を含んでいる。
1 MAKRFYSAEE AAAHCSASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLTRG ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFGAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFANVY TPCQNICIDE SLMLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSTGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCRKPCF EIYHTQLHY(配列番号14628)の配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLTRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFGAT MSRNRYQLLL RFLHFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFANVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLNT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RHWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCRKPCF EIYHTQLHY(配列番号16820)の配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRVDAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFSAT MSRNRYQLLL KFLHFNNEAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHYG RR(配列番号14605)の配列と少なくとも90%一致する配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQVPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLNIPVFSAT MSRNRYQLLL RFLEFNNEAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHY(配列番号14604)の配列と少なくとも90%一致する配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQNVLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFSAT MSRNRYQLLL RFLHFNNDAT AVPPDQPGHD RLHKLRPLID
241 SLTERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHYG RR(配列番号14611)の配列と少なくとも90%一致する配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAP GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQVPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLSIPVFSAT MSRNRYQLLL RFLHFNNEAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHYG RR(配列番号14612)の配列と少なくとも90%一致する配列を含んでいる。
1 MAKRFYSAEE AAAHCMASSS EEFSGSDSEY VPPASESDSS TEESWCSSST VSALEEPMEV
61 DEDVDDLEDQ EAGDRADAAA GGEPAWGPPC NFPPEIPPFT TVPGVKVDTS NFEPINFFQL
121 FMTEAILQDM VLYTNVYAEQ YLTQVPLPRY ARAHAWHPTD IAEMKRFVGL TLAMGLIKAN
181 SLESYWDTTT VLNIPVFSAT MSRNRYQLLL RFLEFNNNAT AVPPDQPGHD RLHKLRPLID
241 SLSERFAAVY TPCQNICIDE SLLLFKGRLQ FRQYIPSKRA RYGIKFYKLC ESSSGYTSYF
301 LIYEGKDSKL DPPGCPPDLT VSGKIVWELI SPLLGQGFHL YVDNFYSSIP LFTALYCLDT
361 PACGTINRNR KGLPRALLDK KLNRGETYAL RKNELLAIKF FDKKNVFMLT SIHDESVIRE
421 QRVGRPPKNK PLCSKEYSKY MGGVDRTDQL QHYYNATRKT RAWYKKVGIY LIQMALRNSY
481 IVYKAAVPGP KLSYYKYQLQ ILPALLFGGV EEQTVPEMPP SDNVARLIGK HFIDTLPPTP
541 GKQRPQKGCK VCRKRGIRRD TRYYCPKCPR NPGLCFKPCF EIYHTQLHYG RR(配列番号14613)の配列と少なくとも90%一致する配列を含んでいる。
1 atggcaccca aaaagaaacg taaagtgatg gccaaaagat tttacagcgc cgaagaagca
61 gcagcacatt gcatggcatc gtcatccgaa gaattctcgg ggagcgattc cgaatatgtc
121 ccaccggcct cggaaagcga ttcgagcact gaggagtcgt ggtgttcctc ctcaactgtc
181 tcggctcttg aggagccgat ggaagtggat gaggatgtgg acgacttgga ggaccaggaa
241 gccggagaca gggccgacgc tgccgcggga ggggagccgg cgtggggacc tccatgcaat
301 tttcctcccg aaatcccacc gttcactact gtgccgggag tgaaggtcga cacgtccaac
361 ttcgaaccga tcaatttctt tcaactcttc atgactgaag cgatcctgca agatatggtg
421 ctctacacta atgtgtacgc cgagcagtac ctgactcaaa acccgctgcc tcgctacgcg
481 agagcgcatg cgtggcaccc gaccgatatc gcggagatga agcggttcgt gggactgacc
541 ctcgcaatgg gcctgatcaa ggccaacagc ctcgagtcat actgggatac cacgactgtg
601 cttagcattc cggtgttctc cgctaccatg tcccgtaacc gctaccaact cctgctgcgg
661 ttcctccact tcaacaacaa tgcgaccgct gtgccacctg accagccagg acacgacaga
721 ctccacaagc tgcggccatt gatcgactcg ctgagcgagc gattcgccgc ggtgtacacc
781 ccttgccaaa acatttgcat cgacgagtcg cttctgctgt ttaaaggccg gcttcagttc
841 cgccagtaca tcccatcgaa gcgcgctcgc tatggtatca aattctacaa actctgcgag
901 tcgtccagcg gctacacgtc atacttcttg atctacgagg ggaaggactc taagctggac
961 ccaccggggt gtccaccgga tcttactgtc tccggaaaaa tcgtgtggga actcatctca
1021 cctctcctcg gacaaggctt tcatctctac gtcgacaatt tctactcatc gatccctctg
1081 ttcaccgccc tctactgcct ggatactcca gcctgtggga ccattaacag aaaccggaag
1141 ggtctgccga gagcactgct ggataagaag ttgaacaggg gagagactta cgcgctgaga
1201 aagaacgaac tcctcgccat caaattcttc gacaagaaaa atgtgtttat gctcacctcc
1261 atccacgacg aatccgtcat ccgggagcag cgcgtgggca ggccgccgaa aaacaagccg
1321 ctgtgctcta aggaatactc caagtacatg gggggtgtcg accggaccga tcagctgcag
1381 cattactaca acgccactag aaagacccgg gcctggtaca agaaagtcgg catctacctg
1441 atccaaatgg cactgaggaa ttcgtatatt gtctacaagg ctgccgttcc gggcccgaaa
1501 ctgtcatact acaagtacca gcttcaaatc ctgccggcgc tgctgttcgg tggagtggaa
1561 gaacagactg tgcccgagat gccgccatcc gacaacgtgg cccggttgat cggaaagcac
1621 ttcattgata ccctgcctcc gacgcctgga aagcagcggc cacagaaggg atgcaaagtt
1681 tgccgcaagc gcggaatacg gcgcgatacc cgctactatt gcccgaagtg cccccgcaat
1741 cccggactgt gtttcaagcc ctgttttgaa atctaccaca cccagttgca ttac(配列番号14626)を含むポリヌクレオチド配列によってコードされる。
1 ttaacctttt tactgccaat gacgcatggg atacgtcgtg gcagtaaaag ggcttaaatg
61 ccaacgacgc gtcccatacg ttgttggcat tttaagtctt ctctctgcag cggcagcatg
121 tgccgccgct gcagagagtt tctagcgatg acagcccctc tgggcaacga gccggggggg
181 ctgtc(配列番号14519)の配列を含んでいる。
1 tttgcatttt tagacattta gaagcctata tcttgttaca gaattggaat tacacaaaaa
61 ttctaccata ttttgaaagc ttaggttgtt ctgaaaaaaa caatatattg ttttcctggg
121 taaactaaaa gtcccctcga ggaaaggccc ctaaagtgaa acagtgcaaa acgttcaaaa
181 actgtctggc aatacaagtt ccactttgac caaaacggct ggcagtaaaa gggttaa(配列番号14520)の配列を含んでいる。
1 ttaacccttt gcctgccaat cacgcatggg atacgtcgtg gcagtaaaag ggcttaaatg
61 ccaacgacgc gtcccatacg ttgttggcat tttaagtctt ctctctgcag cggcagcatg
121 tgccgccgct gcagagagtt tctagcgatg acagcccctc tgggcaacga gccggggggg
181 ctgtc(配列番号14521)の配列を含んでいる。
1 tttgcatttt tagacattta gaagcctata tcttgttaca gaattggaat tacacaaaaa
61 ttctaccata ttttgaaagc ttaggttgtt ctgaaaaaaa caatatattg ttttcctggg
121 taaactaaaa gtcccctcga ggaaaggccc ctaaagtgaa acagtgcaaa acgttcaaaa
181 actgtctggc aatacaagtt ccactttggg acaaatcggc tggcagtgaa agggttaa(配列番号14522)の配列を含んでいる。
1 ttaacctttt tactgccaat gacgcatggg atacgtcgtg gcagtaaaag ggcttaaatg
61 ccaacgacgc gtcccatacg ttgttggcat tttaattctt ctctctgcag cggcagcatg
121 tgccgccgct gcagagagtt tctagcgatg acagcccctc tgggcaacga gccggggggg
181 ctgtc(配列番号14523)の配列を含んでいる。
1 ccctttgcct gccaatcacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgtt(配列番号14573)の配列を含んでいる。
1 cctgggtaaa ctaaaagtcc cctcgaggaa aggcccctaa agtgaaacag tgcaaaacgt
61 tcaaaaactg tctggcaata caagttccac tttgggacaa atcggctggc agtgaaaggg(配列番号14574)の配列を含んでいる。
1 ccctttgcct gccaatcacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgttgt tggcatttta agtcttctct ctgcagcggc agcatgtgcc
121 gccgctgcag agagtttcta gcgatgacag cccctctggg caacgagccg ggggggctgt
181 c(配列番号14579)の配列を含んでいる。
1 cctttttact gccaatgacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgttgt tggcatttta attcttctct ctgcagcggc agcatgtgcc
121 gccgctgcag agagtttcta gcgatgacag cccctctggg caacgagccg ggggggctgt
181 c(配列番号14580)の配列を含んでいる。
1 cctttttact gccaatgacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgttgt tggcatttta agtcttctct ctgcagcggc agcatgtgcc
121 gccgctgcag agagtttcta gcgatgacag cccctctggg caacgagccg ggggggctgt
181 c(配列番号14581)の配列を含んでいる。
1 cctttttact gccaatgacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgttgt tggcatttta agtcttctct ctgcagcggc agcatgtgcc
121 gccgctgcag agag(配列番号14582)の配列を含んでいる。
1 cctttttact gccaatgacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgttgt tggcatttta agtctt(配列番号14583)の配列を含んでいる。
1 ccctttgcct gccaatcacg catgggatac gtcgtggcag taaaagggct taaatgccaa
61 cgacgcgtcc catacgttgt tggcatttta agtctt(配列番号14584)の配列を含んでいる。
1 ttatcctttt tactgccaat gacgcatggg atacgtcgtg gcagtaaaag ggcttaaatg
61 ccaacgacgc gtcccatacg ttgttggcat tttaagtctt ctctctgcag cggcagcatg
121 tgccgccgct gcagagagtt tctagcgatg acagcccctc tgggcaacga gccggggggg
181 ctgtc(配列番号14585)の配列を含んでいる。
1 tttgcatttt tagacattta gaagcctata tcttgttaca gaattggaat tacacaaaaa
61 ttctaccata ttttgaaagc ttaggttgtt ctgaaaaaaa caatatattg ttttcctggg
121 taaactaaaa gtcccctcga ggaaaggccc ctaaagtgaa acagtgcaaa acgttcaaaa
181 actgtctggc aatacaagtt ccactttggg acaaatcggc tggcagtgaa aggg(配列番号14586)の配列を含んでいる。
1 tttgcatttt tagacattta gaagcctata tcttgttaca gaattggaat tacacaaaaa
61 ttctaccata ttttgaaagc ttaggttgtt ctgaaaaaaa caatatattg ttttcctggg
121 taaactaaaa gtcccctcga ggaaaggccc ctaaagtgaa acagtgcaaa acgttcaaaa
181 actgtctggc aatacaagtt ccactttgac caaaacggct ggcagtaaaa ggg(配列番号14587)の配列を含んでいる。
1 ttgttctgaa aaaaacaata tattgttttc ctgggtaaac taaaagtccc ctcgaggaaa
61 ggcccctaaa gtgaaacagt gcaaaacgtt caaaaactgt ctggcaatac aagttccact
121 ttgaccaaaa cggctggcag taaaaggg(配列番号14588)の配列を含んでいる。
1 tttgcatttt tagacattta gaagcctata tcttgttaca gaattggaat tacacaaaaa
61 ttctaccata ttttgaaagc ttaggttgtt ctgaaaaaaa caatatattg ttttcctggg
121 taaactaaaa gtcccctcga ggaaaggccc ctaaagtgaa acagtgcaaa acgttcaaaa
181 actgtctggc aatacaagtt ccactttgac caaaacggct ggcagtaaaa gggttat(配列番号14589)の配列を含んでいる。
1 ttgttctgaa aaaaacaata tattgttttc ctgggtaaac taaaagtccc ctcgaggaaa
61 ggcccctaaa gtgaaacagt gcaaaacgtt caaaaactgt ctggcaatac aagttccact
121 ttgggacaaa tcggctggca gtgaaaggg(配列番号14590)の配列を含んでいる。
1 atcacgcatg ggatacgtcg tggcagtaaa agggcttaaa tgccaacgac gcgtcccata
61 cgtt(配列番号14591)とITRを含んでいる。いくつかの実施態様では、5'トランスポゾン端部は、
1 atgacgcatg ggatacgtcg tggcagtaaa agggcttaaa tgccaacgac gcgtcccata
61 cgttgttggc attttaagtc tt(配列番号14592)とITRを含んでいる。いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンの3'トランスポゾン端部は、
1 cctgggtaaa ctaaaagtcc cctcgaggaa aggcccctaa agtgaaacag tgcaaaacgt
61 tcaaaaactg tctggcaata caagttccac tttgggacaa atcggc(配列番号14593)とITRを含んでいる。いくつかの実施態様では、3'トランスポゾン端部は、
1 ttgttctgaa aaaaacaata tattgttttc ctgggtaaac taaaagtccc ctcgaggaaa
61 ggcccctaaa gtgaaacagt gcaaaacgtt caaaaactgt ctggcaatac aagttccact
121 ttgaccaaaa cggc(配列番号14594)とITRを含んでいる。
1 MASRQRLNHD EIATILENDD DYSPLDSESE KEDCVVEDDV WSDNEDAIVD FVEDTSAQED
61 PDNNIASRES PNLEVTSLTS HRIITLPQRS IRGKNNHVWS TTKGRTTGRT SAINIIRTNR
121 GPTRMCRNIV DPLLCFQLFI TDEIIHEIVK WTNVEIIVKR QNLKDISASY RDTNTMEIWA
181 LVGILTLTAV MKDNHLSTDE LFDATFSGTR YVSVMSRERF EFLIRCIRMD DKTLRPTLRS
241 DDAFLPVRKI WEIFINQCRQ NHVPGSNLTV DEQLLGFRGR CPFRMYIPNK PDKYGIKFPM
301 MCAAATKYMI DAIPYLGKST KTNGLPLGEF YVKDLTKTVH GTNRNITCDN WFTSIPLAKN
361 MLQAPYNLTI VGTIRSNKRE MPEEIKNSRS RPVGSSMFCF DGPLTLVSYK PKPSKMVFLL
421 SSCDENAVIN ESNGKPDMIL FYNQTKGGVD SFDQMCKSMS ANRKTNRWPM AVFYGMLNMA
481 FVNSYIIYCH NKINKQEKPI SRKEFMKKLS IQLTTPWMQE RLQAPTLKRT LRDNITNVLK
541 NVVPASSENI SNEPEPKKRR YCGVCSYKKR RMTKAQCCKC KKAICGEHNI DVCQDCI(配列番号14525)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaaccctag aagcccaatc tacgtaaatt tgacgtatac cgcggcgaaa tatctctgtc
61 tctttcatgt ttaccgtcgg atcgccgcta acttctgaac caactcagta gccattggga
121 cctcgcagga cacagttgcg tcatctcggt aagtgccgcc attttgttgt actctctatt
181 acaacacacg tcacgtcacg tcgttgcacg tcattttgac gtataattgg gctttgtgta
241 acttttgaat ttgtttcaaa ttttttatgt ttgtgattta tttgagttaa tcgtattgtt
301 tcgttacatt tttcatataa taataatatt ttcaggttga gtacaaa(配列番号14570)の配列を含んでいる。いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 agactgtttt tttctaagag acttctaaaa tattattacg agttgattta attttatgaa
61 aacatttaaa actagttgat tttttttata attacataat tttaagaaaa agtgttagag
121 gcttgatttt tttgttgatt ttttctaaga tttgattaaa gtgccataat agtattaata
181 aagagtattt tttaacttaa aatgtatttt atttattaat taaaacttca attatgataa
241 ctcatgcaaa aatatagttc attaacagaa aaaaatagga aaactttgaa gttttgtttt
301 tacacgtcat ttttacgtat gattgggctt tatagctagt taaatatgat tgggcttcta
361 gggttaa(配列番号14528)の配列を含んでいる。
1 MDLRKQDEKI RQWLEQDIEE DSKGESDNSS SETEDIVEME VHKNTSSESE VSSESDYEPV
61 CPSKRQRTQI IESEESDNSE SIRPSRRQTS RVIDSDETDE DVMSSTPQNI PRNPNVIQPS
121 SRFLYGKNKH KWSSAAKPSS VRTSRRNIIH FIPGPKERAR EVSEPIDIFS LFISEDMLQQ
181 VVTFTNAEML IRKNKYKTET FTVSPTNLEE IRALLGLLFN AAAMKSNHLP TRMLFNTHRS
241 GTIFKACMSA ERLNFLIKCL RFDDKLTRNV RQRDDRFAPI RDLWQALISN FQKWYTPGSY
301 ITVDEQLVGF RGRCSFRMYI PNKPNKYGIK LVMAADVNSK YIVNAIPYLG KGTDPQNQPL
361 ATFFIKEITS TLHGTNRNIT MDNWFTSVPL ANELLMAPYN LTLVGTLRSN KREIPEKLKN
421 SKSRAIGTSM FCYDGDKTLV SYKAKSNKVV FILSTIHDQP DINQETGKPE MIHFYNSTKG
481 AVDTVDQMCS SISTNRKTQR WPLCVFYNML NLSIINAYVV YVYNNVRNNK KPMSRRDFVI
541 KLGDQLMEPW LRQRLQTVTL RRDIKVMIQD ILGESSDLEA PVPSVSNVRK IYYLCPSKAR
601 RMTKHRCIKC KQAICGPHNI DICSRCIE(配列番号14530)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaaccctag ataactaaac attcgtccgc tcgacgacgc gctatgccgc gaaattgaag
61 tttacctatt attccgcgtc ccccgccccc gccgcttttt ctagcttcct gatttgcaaa
121 atagtgcatc gcgtgacacg ctcgaggtca cacgacaatt aggtcgaaag ttacaggaat
181 ttcgtcgtcc gctcgacgaa agtttagtaa ttacgtaagt ttggcaaagg taagtgaatg
241 aagtattttt ttataattat tttttaattc tttatagtga taacgtaagg tttatttaaa
301 tttattactt ttatagttat ttagccaatt gttataaatt ccttgttatt gctgaaaaat
361 ttgcctgttt tagtcaaaat ttattaactt ttcgatcgtt ttttag(配列番号14532)の配列を含んでいる。いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tttcactaag taattttgtt cctatttagt agataagtaa cacataatta ttgtgatatt
61 caaaacttaa gaggtttaat aaataataat aaaaaaaaaa tggtttttat ttcgtagtct
121 gctcgacgaa tgtttagtta ttacgtaacc gtgaatatag tttagtagtc tagggttaa(配列番号14571)の配列を含んでいる。
1 MASRQHLYQD EIAAILENED DYSPHDTDSE MEDCVTQDDV RSDVEDEMVD NIGNGTSPAS
61 RHEDPETPDP SSEASNLEVT LSSHRIIILP QRSIREKNNH IWSTTKGQSS GRTAAINIVR
121 TNRGPTRMCR NIVDPLLCFQ LFIKEEIVEE IVKWTNVEMV QKRVNLKDIS ASYRDTNEME
181 IWAIISMLTL SAVMKDNHLS TDELFNVSYG TRYVSVMSRE RFEFLLRLLR MGDKLLRPNL
241 RQEDAFTPVR KIWEIFINQC RLNYVPGTNL TVDEQLLGFR GRCPFRMYIP NKPDKYGIKF
301 PMVCDAATKY MVDAIPYLGK STKTQGLPLG EFYVKELTQT VHGTNRNVTC DNWFTSVPLA
361 KSLLNSPYNL TLVGTIRSNK REIPEEVKNS RSRQVGSSMF CFDGPLTLVS YKPKPSKMVF
421 LLSSCNEDAV VNQSNGKPDM ILFYNQTKGG VDSFDQMCSS MSTNRKTNRW PMAVFYGMLN
481 MAFVNSYIIY CHNMLAKKEK PLSRKDFMKK LSTDLTTPSM QKRLEAPTLK RSLRDNITNV
541 LKIVPQAAID TSFDEPEPKK RRYCGFCSYK KKRMTKTQCF KCKKPVCGEH NIDVCQDCI(配列番号14534)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaaccctag aagcccaatc tacgtcattc tgacgtgtat gtcgccgaaa atactctgtc
61 tctttctcct gcacgatcgg attgccgcga acgctcgatt caacccagtt ggcgccgaga
121 tctattggag gactgcggcg ttgattcggt aagtcccgcc attttgtcat agtaacagta
181 ttgcacgtca gcttgacgta tatttgggct ttgtgttatt tttgtaaatt ttcaacgtta
241 gtttattatt gcatcttttt gttacattac tggtttattt gcatgtatta ctcaaatatt
301 atttttattt tagcgtagaa aataca(配列番号14535)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 agactgtttt ttttgtattt gcattatata ttatattcta aagttgattt aattctaaga
61 aaaacattaa aataagtttc tttttgtaaa atttaattaa ttataagaaa aagtttaagt
121 tgatctcatt ttttataaaa atttgcaatg tttccaaagt tattattgta aaagaataaa
181 taaaagtaaa ctgagtttta attgatgttt tattatatca ttatactata tattacttaa
241 ataaaacaat aactgaatgt atttctaaaa ggaatcacta gaaaatatag tgatcaaaaa
301 tttacacgtc atttttgcgt atgattgggc tttataggtt ctaaaaatat gattgggcct
361 ctagggttaa(配列番号14536)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、CCCTAGAAGCCCAATC(配列番号14564)というITR配列を含んでいる。
1 MESRQRLNQD EIATILENDD DYSPLDSDSE AEDRVVEDDV WSDNEDAMID YVEDTSRQED
61 PDNNIASQES ANLEVTSLTS HRIISLPQRS ICGKNNHVWS TTKGRTTGRT SAINIIRTNR
121 GPTRMCRNIV DPLLCFQLFI TDEIIHEIVK WTNVEMIVKR QNLIDISASY RDTNTMEMWA
181 LVGILTLTAV MKDNHLSTDE LFDATFSGTR YVSVMSRERF EFLIRCMRMD DKTLRPTLRS
241 DDAFIPVRKL WEIFINQCRL NYVPGGNLTV DEQLLGFRGR CPFRMYIPNK PDKYGIRFPM
301 MCDAATKYMI DAIPYLGKST KTNGLPLGEF YVKELTKTVH GTNRNVTCDN WFTSIPLAKN
361 MLQAPYNLTI VGTIRSNKRE IPEEIKNSRS RPVGSSMFCF DGPLTLVSYK PKPSRMVFLL
421 SSCDENAVIN ESNGKPDMIL FYNQTKGGVD SFDQMCKSMS ANRKTNRWPM AVFYGMLNMA
481 FVNSYIIYCH NKINKQKKPI NRKEFMKNLS TDLTTPWMQE RLKAPTLKRT LRDNITNVLK
541 NVVPPSPANN SEEPGPKKRS YCGFCSYKKR RMTKTQFYKC KKAICGEHNI DVCQDCV(配列番号14537)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaaccctag aagcccaatc tacgtaaatt tgacgtatac cgcggcgaaa tatatctgtc
61 tctttcacgt ttaccgtcgg attcccgcta acttcggaac caactcagta gccattgaga
121 actcccagga cacagttgcg tcatctcggt aagtgccgcc attttgttgt aatagacagg
181 ttgcacgtca ttttgacgta taattgggct ttgtgtaact tttgaaatta tttataattt
241 ttattgatgt gatttatttg agttaatcgt attgtttcgt tacatttttc atatgatatt
301 aatattttca gattgaatat aaa(配列番号14538)の配列を含んでいる。いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 agactgtttt ttttaaaagg cttataaagt attactattg cgtgatttaa ttttataaaa
61 atatttaaaa ccagttgatt tttttaataa ttacctaatt ttaagaaaaa atgttagaag
121 cttgatattt ttgttgattt ttttctaaga tttgattaaa aggccataat tgtattaata
181 aagagtattt ttaacttcaa atttatttta tttattaatt aaaacttcaa ttatgataat
241 acatgcaaaa atatagttca tcaacagaaa aatataggaa aactctaata gttttatttt
301 tacacgtcat ttttacgtat gattgggctt tatagctagt caaatatgat tgggcttcta
361 gggttaa(配列番号14539)の配列を含んでいる。
1 MNGKDSLGEF YLDDLSDCLD CRSASSTDDE SDSSNIAIRK RCPIPLIYSD SEDEDMNNNV
61 EDNNHFVKES NRYHYQIVEK YKITSKTKKW KDVTVTEMKK FLGLIILMGQ VKKDVLYDYW
121 STDPSIETPF FSKVMSRNRF LQIMQSWHFY NNNDISPNSH RLVKIQPVID YFKEKFNNVY
181 KSDQQLSLDE CLIPWRGRLS IKTYNPAKIT KYGILVRVLS EARTGYVSNF CVYAADGKKI
241 EETVLSVIGP YKNMWHHVYQ DNYYNSVNIA KIFLKNKLRV CGTIRKNRSL PQILQTVKLS
301 RGQHQFLRNG HTLLEVWNNG KRNVNMISTI HSAQMAESRN RSRTSDCPIQ KPISIIDYNK
361 YMKGVDRADQ YLSYYSIFRK TKKWTKRVVM FFINCALFNS FKVYTTLNGQ KITYKNFLHK
421 AALSLIEDCG TEEQGTDLPN SEPTTTRTTS RVDHPGRLEN FGKHKLVNIV TSGQCKKPLR
481 QCRVCASKKK LSRTGFACKY CNVPLHKGDC FERYHSLKKY(配列番号14540)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaaataatg cccactctag atgaacttaa cactttaccg accggccgtc gattattcga
61 cgtttgctcc ccagcgctta ccgaccggcc atcgattatt cgacgtttgc ttcccagcgc
121 ttaccgaccg gtcatcgact tttgatcttt ccgttagatt tggttaggtc agattgacaa
181 gtagcaagca tttcgcattc tttattcaaa taatcggtgc ttttttctaa gctttagccc
241 ttagaa(配列番号14541)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 acaacttctt ttttcaacaa atattgttat atggattatt tatttattta tttatttatg
61 gtatatttta tgtttattta tttatggtta ttatggtata ttttatgtaa ataataaact
121 gaaaacgatt gtaatagatg aaataaatat tgttttaaca ctaatataat taaagtaaaa
181 gattttaata aatttcgtta ccctacaata acacgaagcg tacaatttta ccagagttta
241 ttaa(配列番号14542)の配列を含んでいる。
1 MNEKNGIGEF YLDDLSDCPD SYSRSNSGDE SDGSDTIIRK RGSVLPPRYS DSEDDEINNV
61 EDNANNVENN DDIWSTNDEA IILEPFEGSP GLKIMPSSAE SVTDNVNLFF GDDFFEHLVR
121 ESNRYHYQVM EKYKIPSKAK KWTDITVPEM KKFLGLIVLM GQIKKDVLYD YWSTDPSIET
181 PFFSQVMSRN RFVQIMQSWH FCNNDNIPHD SHRLAKIQPV IDYFRRKFND VYKPCQQLSL
241 DESIIPWRGR LSIKTYNPAK ITKYGILVRV LSEAVTGYVC NFDVYAADGK KLEDTAVIEP
301 YKNIWHQIYQ DNYYNSVKMA RILLKNKVRV CGTIRKNRGL PRSLKTIQLS RGQYEFRRNH
361 QILLEVWNNG RRNVNMISTI HSAQLMESRS KSKRSDVPIQ KPNSIIDYNK YMKGVDRADQ
421 YLAYYSIFRK TKKWTKRVVM FFINCALFNS FRVYTILNGK NITYKNFLHK VAVSWIEDGE
481 TNCTEQDDNL PNSEPTRRAP RLDHPGRLSN YGKHKLINIV TSGRSLKPQR QCRVCAVQKK
541 RSRTCFVCKF CNVPLHKGDC FERYHTLKKY(配列番号14543)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaatttttt aacattttac cgaccgatag ccgattaatc gggtttttgc cgctgacgct
61 taccgaccga taacctatta atcggctttt tgtcgtcgaa gcttaccaac ctatagccta
121 cctatagtta atcggttgcc atggcgataa acaatctttc tcattatatg agcagtaatt
181 tgttatttag tactaaggta ccttgctcag ttgcgtcagt tgcgttgctt tgtaagctcc
241 cacagtttta taccaattcg aaaaacttac cgttcgcg(配列番号14544)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 actatttcac atttgaacta aaaaccgttg taatagataa aataaatata atttagtatt
61 aatattatgg aaacaaaaga ttttattcaa tttaattatc ctatagtaac aaaaagcggc
121 caattttatc tgagcatacg aaaagcacag atactcccgc ccgacagtct aaaccgaaac
181 agagccggcg ccagggagaa tctgcgcctg agcagccggt cggacgtgcg tttgctgttg
241 aaccgctagt ggtcagtaaa ccagaaccag tcagtaagcc agtaactgat cagttaacta
301 gattgtatag ttcaaattga acttaatcta gtttttaagc gtttgaatgt tgtctaactt
361 cgttatatat tatattcttt ttaa(配列番号14545)の配列を含んでいる。
1 MFSFVPNKEQ TRTVLIFCFH LKTTAAESHR PLVEAFGEQV PTVKTCERWF QRFKSGDFDV
61 DDKEHGKPPK RYEDAELQAL LDEDDAQTQK QLAEQLEVSQ QAVSNRLREG GKIQKVGRWV
121 PHELNERQRE RRKNTCEILL SRYKRKSFLH RIVTGEEKWI FFVNPKRKKS YVDPGQPATS
181 TARPNRFGKK TRLCVWWDQS GVIYYELLKP GETVNTARYQ QQLINLNRAL QRKRPEYQKR
241 QHRVIFLHDN APSHTARAVR DTLETLNWEV LPHAAYSPDL APSDYHLFAS MGHALAEQRF
301 DSYESVEEWL DEWFAAKDDE FYWRGIHKLP ERWDNCVASD GKYFE(配列番号14546)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttattgggtt gcccaaaaag taattgcgga tttttcatat acctgtcttt taaacgtaca
61 tagggatcga actcagtaaa actttgacct tgtgaaataa caaacttgac tgtccaacca
121 ccatagtttg gcgcgaattg agcgtcataa ttgttttgac tttttgcagt caac(配列番号14547)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 atgatttttt ctttttaaac caattttaat tagttaattg atataaaaat ccgcaattac
61 tttttgggca acccaataa(配列番号14548)の配列を含んでいる。
1 MENFENWRKR RHLREVLLGH FFAKKTAAES HRLLVEVYGE HALAKTQCFE WFQRFKSGDF
61 DTEDKERPGQ PKKFEDEELE ALLDEDCCQT QEELAKSLGV TQQAISKRLK AAGYIQKQGN
121 WVPHELKPRD VERRFCMSEM LLQRHKKKSF LSRIITGDEK WIHYDNSKRK KSYVKRGGRA
181 KSTPKSNLHG AKVMLCIWWD QRGVLYYELL EPGQTITGDL YRTQLIRLKQ ALAEKRPEYA
241 KRHGAVIFHH DNARPHVALP VKNYLENSGW EVLPHPPYSP DLAPSDYHLF RSMQNDLAGK
301 RFTSEQGIRK WLDSFLAAKP AKFFEKGIHE LSERWEKVIA SDGQYFE(配列番号14549)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 taagacttcc aaaatttcca cccgaacttt accttccccg cgcattatgt ctctcttttc
61 accctctgat ccctggtatt gttgtcgagc acgatttata ttgggtgtac aacttaaaaa
121 ccggaattgg acgctagatg tccacactaa cgaatagtgt aaaagcacaa atttcatata
181 tacgtcattt tgaaggtaca tttgacagct atcaaaatca gtcaataaaa ctattctatc
241 tgtgtgcatc atattttttt attaact(配列番号14550)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tgcattcatt cattttgtta tcgaaataaa gcattaattt tcactaaaaa attccggttt
61 ttaagttgta cacccaatat catccttagt gacaattttc aaatggcttt cccattgagc
121 tgaaaccgtg gctctagtaa gaaaaacgcc caacccgtca tcatatgcct tttttttctc
181 aacatccg(配列番号14551)の配列を含んでいる。
1 MENQKEHYRH ILLFYFRKGK NASQAHKKLC AVYGDEALKE RQCQNWFDKF RSGDFSLKDE
61 KRSGRPVEVD DDLIKAIIDS DRHSTTREIA EKLHVSHTCI ENHLKQLGYV QKLDTWVPHE
121 LKEKHLTQRI NSCDLLKKRN ENDPFLKRLI TGDEKWVVYN NIKRKRSWSR PREPAQTTSK
181 AGIHRKKVLL SVWWDYKGIV YFELLPPNRT INSVVYIEQL TKLNNAVEEK RPELTNRKGV
241 VFHHDNARPH TSLVTRQKLL ELGWDVLPHP PYSPDLAPSD YFLFRSLQNS LNGKNFNNDD
301 DIKSYLIQFF ANKNQKFYER GIMMLPERWQ KVIDQNGQHI TE(配列番号14552)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttgggttggc aactaagtaa ttgcggattt cactcataga tggcttcagt tgaattttta
61 ggtttgctgg cgtagtccaa atgtaaaaca cattttgtta tttgatagtt ggcaattcag
121 ctgtcaatca gtaaaaaaag ttttttgatc ggttgcgtag ttttcgtttg gcgttcgttg
181 aaaa(配列番号14553)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 agttatttag ttccatgaaa aaattgtctt tgattttcta aaaaaaatcc gcaattactt
61 agttgccaat ccaa(配列番号14554)の配列を含んでいる。
1 MSSFVPENVH LRHALLFLFH QKKRAAESHR LLVETYGEHA PTIRTCETWF RQFKCGDFNV
61 QDKERPGRPK TFEDAELQEL LDEDSTQTQK QLAEKLNVSR VAICERLQAM GKIQKMGRWV
121 PHELNDRQME NRKIVSEMLL QRYERKSFLH RIVTGDEKWI YFENPKRKKS WLSPGEAGPS
181 TARPNRFGRK TMLCVWWDQI GVVYYELLKP GETVNTDRYR QQMINLNCAL IEKRPQYAQR
241 HDKVILQHDN APSHTAKPVK EMLKSLGWEV LSHPPYSPDL APSDYHLFAS MGHALAEQHF
301 ADFEEVKKWL DEWFSSKEKL FFWNGIHKLS ERWTKCIESN GQYFE(配列番号14555)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 agtcagaaat gacacctcga tcgacgacta atcgacgtct aatcgacgtc gattttatgt
61 caacatgtta ccaggtgtgt cggtaattcc tttccggttt ttccggcaga tgtcactagc
121 cataagtatg aaatgttatg atttgataca tatgtcattt tattctactg acattaacct
181 taaaactaca caagttacgt tccgccaaaa taacagcgtt atagatttat aattttttga
241 aa(配列番号14556)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 ataaatttga actatccatt ctaagtaacg tgttttcttt aacgaaaaaa ccggaaaaga
61 attaccgaca ctcctggtat gtcaacatgt tattttcgac attgaatcgc gtcgattcga
121 agtcgatcga ggtgtcattt ctgact(配列番号14557)の配列を含んでいる。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPKEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14558)と少なくとも5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、99%、またはこれらの間の任意の割合が一致するアミノ酸配列を含むか、このアミノ酸配列からなることができる。
1 ttaaccctag aaagatagtc tgcgtaaaat tgacgcatgc attcttgaaa tattgctctc
61 tctttctaaa tagcgcgaat ccgtcgctgt gcatttagga catctcagtc gccgcttgga
121 gctcccgtga ggcgtgcttg tcaatgcggt aagtgtcact gattttgaac tataacgacc
181 gcgtgagtca aaatgacgca tgattatctt ttacgtgact tttaagattt aactcatacg
241 ataattatat tgttatttca tgttctactt acgtgataac ttattatata tatattttct
301 tgttatagat atc(配列番号14559)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tttgttactt tatagaagaa attttgagtt tttgtttttt tttaataaat aaataaacat
61 aaataaattg tttgttgaat ttattattag tatgtaagtg taaatataat aaaacttaat
121 atctattcaa attaataaat aaacctcgat atacagaccg ataaaacaca tgcgtcaatt
181 ttacgcatga ttatctttaa cgtacgtcac aatatgatta tctttctagg gttaa(配列番号14560)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 ccctagaaag atagtctgcg taaaattgac gcatgcattc ttgaaatatt gctctctctt
61 tctaaatagc gcgaatccgt cgctgtgcat ttaggacatc tcagtcgccg cttggagctc
121 ccgtgaggcg tgcttgtcaa tgcggtaagt gtcactgatt ttgaactata acgaccgcgt
181 gagtcaaaat gacgcatgat tatcttttac gtgactttta agatttaact catacgataa
241 ttatattgtt atttcatgtt ctacttacgt gataacttat tatatatata ttttcttgtt
301 atagatatc(配列番号14561)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tttgttactt tatagaagaa attttgagtt tttgtttttt tttaataaat aaataaacat
61 aaataaattg tttgttgaat ttattattag tatgtaagtg taaatataat aaaacttaat
121 atctattcaa attaataaat aaacctcgat atacagaccg ataaaacaca tgcgtcaatt
181 ttacgcatga ttatctttaa cgtacgtcac aatatgatta tctttctagg g(配列番号14562)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tctaaatagc gcgaatccgt cgctgtgcat ttaggacatc tcagtcgccg cttggagctc
61 ccgtgaggcg tgcttgtcaa tgcggtaagt gtcactgatt ttgaactata acgaccgcgt
121 gagtcaaaat gacgcatgat tatcttttac gtgactttta agatttaact catacgataa
181 ttatattgtt atttcatgtt ctacttacgt gataacttat tatatatata ttttcttgtt
241 atagatatc(配列番号14609)の配列を含んでいる。
いくつかの実施態様では、piggyBacトランスポゾンまたはpiggyBac様トランスポゾンは、
1 tttgttactt tatagaagaa attttgagtt tttgtttttt tttaataaat aaataaacat
61 aaataaattg tttgttgaat ttattattag tatgtaagtg taaatataat aaaacttaat
121 atctattcaa attaataaat aaacctcgat atacagaccg ataaaacaca tgcgtcaatt
181 ttacgcatga ttatctttaa cgtacgtcac aatatgatta tctttctagg g(配列番号14610)の配列を含んでいる。
CG(配列番号14567)というITR配列を含んでいる。
ATAACTAAAC(配列番号14568)というITR配列を含んでいる。
1 MMLNWLKSGK LESQSQEQSS CYLENSNCLP PTLDSTDIIG EENKAGTTSR KKRKYDEDYL
61 NFGFTWTGDK DEPNGLCVIC EQVVNNSSLN PAKLKRHLDT KHPTLKGKSE YFKRKCNELN
121 QKKHTFERYV RDDNKNLLKA SYLVSLRIAK QGEAYTIAEK LIKPCTKDLT TCVFGEKFAS
181 KVDLVPLSDT TISRRIEDMS YFCEAVLVNR LENAKCGFTL QMDESTDVAG LAILLVFVRY
241 IHESSFEEDM LFCKALPTQT TGEEIFNLLN AYFEKHSIPW NLCYHICTDG AKAMVGVIKG
301 VIARIKKLVP DIKASHCCLH RHALAVKRIP NALHEVLNDA VKMINFIKSR PLNARVFALL
361 CDDLGSLHKN LLLHTEVRWL SRGKVLTRFW ELRDEIRIFF NEREFAGKLN DTSWLQNLAY
421 IADIFSYLNE VNLSLQGPNS TIFKVNSRIN SIKSKLKLWE ECITKNNTEC FANLNDFLET
481 SNTALDPNLK SNILEHLNGL KNTFLEYFPP TCNNISWVEN PFNECGNVDT LPIKEREQLI
541 DIRTDTTLKS SFVPDGIGPF WIKLMDEFPE ISKRAVKELM PFVTTYLCEK SFSVYVATKT
601 KYRNRLDAED DMRLQLTTIH PDIDNLCNNK QAQKSH(GenBank登録番号ABF20545と配列番号17900)のアミノ酸配列を含むか、このアミノ酸配列からなる。
1 MMLNWLKSGK LESQSQEQSS CYLENSNCLP PTLDSTDIIG EENKAGTTSR KKRKYDEDYL
61 NFGFTWTGDK DEPNGLCVIC EQVVNNSSLN PAKLKRHLDT KHPTLKGKSE YFKRKCNELN
121 QKKHTFERYV RDDNKNLLKA SYLVSLRIAK QGEAYTIAEK LIKPCTKDLT TCVFGEKFAS
181 KVDLVPLSDT TISRRIEDMS YFCEAVLVNR LENAKCGFTL QMDESTDVAG LAILLVFVRY
241 IHESSFEEDM LFCKALPTQT TGEEIFNLLN AYFEKHSIPW NLCYHICTDG AKAMVGVIKG
301 VIARIKKLVP DIKASHCCLH RHALAVKRIP NALHEVLNDA VKMINFIKSR PLNARVFALL
361 CDDLGSLHKN LLLHTEVRWL SRGKVLTRFW ELRDEIRIFF NEREFAGKLN DTSWLQNLAY
421 IADIFSYLNE VNLSLQGPNS TIFKVNSRIN SIKSKLKLWE ECITKNNTEC FANLNDFLET
481 SNTALDPNLK SNILEHLNGL KNTFLEYFPP TCNNISWVEN PFNECGNVDT LPIKEREQLI
541 DIRTDTTLKS SFVPDGIGPF WIKLMDEFPE ISKRAVKELM PFVTTYLCEK SFSVYVATKT
601 KYRNRLDAED DMRLQLTTIH PDIDNLCNNK QAQKSH(GenBank登録番号ABF20545と配列番号17900)のアミノ酸配列を含むか、このアミノ酸配列からなる野生型TcBusterトランスポザーゼと少なくとも20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、97%、99%、またはこれらの間の任意の割合が一致する配列を含むか、この配列からなることができる。
1 atgatgttga attggctgaa aagtggaaag cttgaaagtc aatcacagga acagagttcc
61 tgctaccttg agaactctaa ctgcctgcca ccaacgctcg attctacaga tattatcggt
121 gaagagaaca aagctggtac cacctctcgc aagaagcgga aatatgacga ggactatctg
181 aacttcggtt ttacatggac tggcgacaag gatgagccca acggactttg tgtgatttgc
241 gagcaggtag tcaacaattc ctcacttaac ccggccaaac tgaaacgcca tttggacaca
301 aagcatccga cgcttaaagg caagagcgaa tacttcaaaa gaaaatgtaa cgagctcaat
361 caaaagaagc atacttttga gcgatacgta agggacgata acaagaacct cctgaaagct
421 tcttatctcg tcagtttgag aatagctaaa cagggcgagg catataccat agcggagaag
481 ttgatcaagc cttgcaccaa ggatctgaca acttgcgtat ttggagaaaa attcgcgagc
541 aaagttgatc tcgtccccct gtccgacacg actatttcaa ggcgaatcga agacatgagt
601 tacttctgtg aagccgtgct ggtgaacagg ttgaaaaatg ctaaatgtgg gtttacgctg
661 cagatggacg agtcaacaga tgttgccggt cttgcaatcc tgcttgtgtt tgttaggtac
721 atacatgaaa gctcttttga ggaggatatg ttgttctgca aagcacttcc cactcagacg
781 acaggggagg agattttcaa tcttctcaat gcctatttcg aaaagcactc catcccatgg
841 aatctgtgtt accacatttg cacagacggt gccaaggcaa tggtaggagt tattaaagga
901 gtcatagcga gaataaaaaa actcgtccct gatataaaag ctagccactg ttgcctgcat
961 cgccacgctt tggctgtaaa gcgaataccg aatgcattgc acgaggtgct caatgacgct
1021 gttaaaatga tcaacttcat caagtctcgg ccgttgaatg cgcgcgtctt cgctttgctg
1081 tgtgacgatt tggggagcct gcataaaaat cttcttcttc ataccgaagt gaggtggctg
1141 tctagaggaa aggtgctgac ccgattttgg gaactgagag atgaaattag aattttcttc
1201 aacgaaaggg aatttgccgg gaaattgaac gacaccagtt ggttgcaaaa tttggcatat
1261 atagctgaca tattcagtta tctgaatgaa gttaatcttt ccctgcaagg gccgaatagc
1321 acaatcttca aggtaaatag ccgcattaac agtattaaat caaagttgaa gttgtgggaa
1381 gagtgtataa cgaaaaataa cactgagtgt tttgcgaacc tcaacgattt tttggaaact
1441 tcaaacactg cgttggatcc aaacctgaag tctaatattt tggaacatct caacggtctt
1501 aagaacacct ttctggagta ttttccacct acgtgtaata atatctcctg ggtggagaat
1561 cctttcaatg aatgcggtaa cgtcgataca ctcccaataa aagagaggga acaattgatt
1621 gacatacgga ctgatacgac attgaaatct tcattcgtgc ctgatggtat aggaccattc
1681 tggatcaaac tgatggacga atttccagaa attagcaaac gagctgtcaa agagctcatg
1741 ccatttgtaa ccacttacct ctgtgagaaa tcattttccg tctatgtagc cacaaaaaca
1801 aaatatcgaa atagacttga tgctgaagac gatatgcgac tccaacttac tactatccat
1861 ccagacattg acaacctttg taacaacaag caggctcaga aatcccactg a(GenBank登録番号DQ481197と配列番号17901)の配列を含むか、この配列からなる核酸配列によってコードされている。
1 atgatgttga attggctgaa aagtggaaag cttgaaagtc aatcacagga acagagttcc
61 tgctaccttg agaactctaa ctgcctgcca ccaacgctcg attctacaga tattatcggt
121 gaagagaaca aagctggtac cacctctcgc aagaagcgga aatatgacga ggactatctg
181 aacttcggtt ttacatggac tggcgacaag gatgagccca acggactttg tgtgatttgc
241 gagcaggtag tcaacaattc ctcacttaac ccggccaaac tgaaacgcca tttggacaca
301 aagcatccga cgcttaaagg caagagcgaa tacttcaaaa gaaaatgtaa cgagctcaat
361 caaaagaagc atacttttga gcgatacgta agggacgata acaagaacct cctgaaagct
421 tcttatctcg tcagtttgag aatagctaaa cagggcgagg catataccat agcggagaag
481 ttgatcaagc cttgcaccaa ggatctgaca acttgcgtat ttggagaaaa attcgcgagc
541 aaagttgatc tcgtccccct gtccgacacg actatttcaa ggcgaatcga agacatgagt
601 tacttctgtg aagccgtgct ggtgaacagg ttgaaaaatg ctaaatgtgg gtttacgctg
661 cagatggacg agtcaacaga tgttgccggt cttgcaatcc tgcttgtgtt tgttaggtac
721 atacatgaaa gctcttttga ggaggatatg ttgttctgca aagcacttcc cactcagacg
781 acaggggagg agattttcaa tcttctcaat gcctatttcg aaaagcactc catcccatgg
841 aatctgtgtt accacatttg cacagacggt gccaaggcaa tggtaggagt tattaaagga
901 gtcatagcga gaataaaaaa actcgtccct gatataaaag ctagccactg ttgcctgcat
961 cgccacgctt tggctgtaaa gcgaataccg aatgcattgc acgaggtgct caatgacgct
1021 gttaaaatga tcaacttcat caagtctcgg ccgttgaatg cgcgcgtctt cgctttgctg
1081 tgtgacgatt tggggagcct gcataaaaat cttcttcttc ataccgaagt gaggtggctg
1141 tctagaggaa aggtgctgac ccgattttgg gaactgagag atgaaattag aattttcttc
1201 aacgaaaggg aatttgccgg gaaattgaac gacaccagtt ggttgcaaaa tttggcatat
1261 atagctgaca tattcagtta tctgaatgaa gttaatcttt ccctgcaagg gccgaatagc
1321 acaatcttca aggtaaatag ccgcattaac agtattaaat caaagttgaa gttgtgggaa
1381 gagtgtataa cgaaaaataa cactgagtgt tttgcgaacc tcaacgattt tttggaaact
1441 tcaaacactg cgttggatcc aaacctgaag tctaatattt tggaacatct caacggtctt
1501 aagaacacct ttctggagta ttttccacct acgtgtaata atatctcctg ggtggagaat
1561 cctttcaatg aatgcggtaa cgtcgataca ctcccaataa aagagaggga acaattgatt
1621 gacatacgga ctgatacgac attgaaatct tcattcgtgc ctgatggtat aggaccattc
1681 tggatcaaac tgatggacga atttccagaa attagcaaac gagctgtcaa agagctcatg
1741 ccatttgtaa ccacttacct ctgtgagaaa tcattttccg tctatgtagc cacaaaaaca
1801 aaatatcgaa atagacttga tgctgaagac gatatgcgac tccaacttac tactatccat
1861 ccagacattg acaacctttg taacaacaag caggctcaga aatcccactg a(GenBank登録番号DQ481197と配列番号17901)の配列を含むか、この配列からなる核酸配列によってコードされている野生型TcBusterトランスポザーゼと少なくとも20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、97%、99%、またはこれらの間の任意の割合が一致する配列を含むか、この配列からなることができる。
1 Cagtgttctt caacctttgc catccggcgg aaccctttgt cgagatattt ttttttatgg
61 aacccttcat ttagtaatac acccagatga gattttaggg acagctgcgt tgacttgtta
121 cgaacaaggt gagcccgtgc tttggtctag ccaagggcat ggtaaagact atattcgcgg
181 cgttgtgaca atttaccgaa caactccgcg gccgggaagc cgatctcggc ttgaacgaat
241 tgttaggtgg cggtacttgg gtcgatatca aagtgcatca cttcttcccg tatgcccaac
301 tttgtataga gagccactgc gggatcgtca ccgtaatctg cttgcacgta gatcacataa
361 gcaccaagcg cgttggcctc atgcttgagg agattgatga gcgcggtggc aatgccctgc
421 ctccggtgct cgccggagac tgcgagatca tagatata(配列番号17902)の配列を含むか、この配列からなる5'逆方向反復を認識する。
本開示の組成物と方法のいくつかの実施態様では、TcBusterトランスポザーゼは、
1 gatatcaagc ttatcgatac cgtcgacctc gagatttctg aacgattcta ggttaggatc
61 aaacaaaata caatttattt taaaactgta agttaactta cctttgcttg tctaaaccaa
121 aaacaacaac aaaactacga ccacaagtac agttacatat ttttgaaaat taaggttaag
181 tgcagtgtaa gtcaactatg cgaatggata acatgtttca acatgaaact ccgattgacg
241 catgtgcatt ctgaagagcg gcgcggccga cgtctctcga attgaagcaa tgactcgcgg
301 aaccccgaaa gcctttgggt ggaaccctag ggttccgcgg aacacaggtt gaagaacact
361 g(配列番号17903)の配列を含むか、この配列からなる3'逆方向反復を認識する。
1 Cctgcaggag tgttcttcaa cctttgccat ccggcggaac cctttgtcga gatatttttt
61 tttatggaac ccttcattta gtaatacacc cagatgagat tttagggaca gctgcgttga
121 cttgttacga acaaggtgag cccgtgcttt ggtaataaaa actctaaata agatttaaat
181 ttgcatttat ttaaacaaac tttaaacaaa aagataaata ttccaaataa aataatatat
241 aaaataaaaa ataaaaatta atgacttttt tgcgcttgct tattattgca caaattatca
301 atatcgggat ggatcgttgt ttttt(配列番号17904)の配列を含むか、この配列からなる5'逆方向反復を認識する。
1 Gagccaattc agcatcatat ttctgaacga ttctaggtta ggatcaaaca aaatacaatt
61 tattttaaaa ctgtaagtta acttaccttt gcttgtctaa acctaaaaca acaacaaaac
121 tacgaccaca agtacagtta catatttttg aaaattaagg ttaagtgcag tgtaagtcaa
181 ctatgcgaat ggataacatg tttcaacatg aaactccgat tgacgcatgt gcattctgaa
241 gagcggcgcg gccgacgtct ctcgaattga agcaatgact cgcggaaccc cgaaagcctt
301 tgggtggaac cctagggttc cgcggaacac aggttgaaga acactg(配列番号17905)の配列を含むか、この配列からなる3'逆方向反復を認識する。
転移に基づかない遺伝子改変法
センチリン
CARTyrinの作製と生成
CARTyrinタンパク質のスクリーニング
核酸分子
本明細書に記載のポリヌクレオチドに選択的にハイブリダイズするポリヌクレオチド
核酸の構成
核酸を構成するための組み換え法
核酸をスクリーニングする方法と単離する方法
核酸を構成するための合成法
組み換え発現カセット
ナノトランスポゾン
1 MVGSLNCIVA VSQNMGIGKN GDFPWPPLRN ESRYFQRMTT TSSVEGKQNL
61 VIMGKKTWFS IPEKNRPLKG RINLVLSREL KEPPQGAHFL SRSLDDALKL
121 TEQPELANKV DMVWIVGGSS VYKEAMNHPG HLKLFVTRIM QDFESDTFFP
181 EIDLEKYKLL PEYPGVLSDV QEEKGIKYKF EVYEKND(配列番号17012)のアミノ酸配列を含むか、このアミノ酸配列からなる。いくつかの実施態様では、DHFR突然変異タンパク質酵素は、atggtcgggtctctgaattgtatcgtcgccgtgagtcagaacatgggcattgggaagaatggcgatttcccatggccacctctgcgcaacgagtcccgatactttcagcggatgacaactacctcctctgtggaagggaaacagaatctggtcatcatgggaaagaaaacttggttcagcattccagagaagaaccggcccctgaaaggcagaatcaatctggtgctgtcccgagaactgaaggagccaccacagggagctcactttctgagccggtccctggacgatgcactgaagctgacagaacagcctgagctggccaacaaagtcgatatggtgtggatcgtcgggggaagttcagtgtataaggaggccatgaatcaccccggccatctgaaactgttcgtcacacggatcatgcaggactttgagagcgatactttctttcctgaaattgacctggagaagtacaaactgctgcccgaatatcctggcgtgctgtccgatgtccaggaagagaaaggcatcaaatacaagttcgaggtctatgagaagaatgac(配列番号17095)の配列を含むか、この配列からなる核酸配列によってコードされている。いくつかの実施態様では、DHFR突然変異タンパク質酵素のアミノ酸配列は、80位、113位、153位のうちの1つ以上に変異をさらに含んでいる。いくつかの実施態様では、DHFR突然変異タンパク質酵素のアミノ酸配列は、80位におけるフェニルアラニン(F)またはロイシン(L)の置換、113位におけるロイシン(L)またはバリン(V)の置換、153位におけるバリン(V)またはアスパラギン酸(D)の置換のうちの1つ以上を含んでいる。
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)のアミノ酸配列と少なくとも20%一致するアミノ酸配列を持つpiggyBacトランスポザーゼによって認識される。いくつかの実施態様では、第1の逆方向末端反復(ITR)をコードする配列、または第2の逆方向末端反復(ITR)をコードする配列は、
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEI SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTGATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RMYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPNEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14487)のアミノ酸配列を持つpiggyBacトランスポザーゼによって認識される。いくつかの実施態様では、第1の逆方向末端反復(ITR)をコードする配列、または第2の逆方向末端反復(ITR)をコードする配列は、
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPKEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14484)のアミノ酸配列と少なくとも20%一致するアミノ酸配列を持つpiggyBacトランスポザーゼによって認識される。いくつかの実施態様では、第1の逆方向末端反復(ITR)をコードする配列、または第2の逆方向末端反復(ITR)をコードする配列は、
1 MGSSLDDEHI LSALLQSDDE LVGEDSDSEV SDHVSEDDVQ SDTEEAFIDE VHEVQPTSSG
61 SEILDEQNVI EQPGSSLASN RILTLPQRTI RGKNKHCWST SKSTRRSRVS ALNIVRSQRG
121 PTRMCRNIYD PLLCFKLFFT DEIISEIVKW TNAEISLKRR ESMTSATFRD TNEDEIYAFF
181 GILVMTAVRK DNHMSTDDLF DRSLSMVYVS VMSRDRFDFL IRCLRMDDKS IRPTLRENDV
241 FTPVRKIWDL FIHQCIQNYT PGAHLTIDEQ LLGFRGRCPF RVYIPNKPSK YGIKILMMCD
301 SGTKYMINGM PYLGRGTQTN GVPLGEYYVK ELSKPVHGSC RNITCDNWFT SIPLAKNLLQ
361 EPYKLTIVGT VRSNKREIPE VLKNSRSRPV GTSMFCFDGP LTLVSYKPKP AKMVYLLSSC
421 DEDASINEST GKPQMVMYYN QTKGGVDTLD QMCSVMTCSR KTNRWPMALL YGMINIACIN
481 SFIIYSHNVS SKGEKVQSRK KFMRNLYMSL TSSFMRKRLE APTLKRYLRD NISNILPKEV
541 PGTSDDSTEE PVMKKRTYCT YCPSKIRRKA NASCKKCKKV ICREHNIDMC QSCF(配列番号14484)のアミノ酸配列を持つpiggyBacトランスポザーゼによって認識される。
MAPKKKRKVEGIKSNISLLKDELRGQISHISHEYLSLIDLAFDSKQNRLFEMKVLELLVNEYGFKGRHLGGSRKPDGIVYSTTLEDNFGIIVDTKAYSEGYSLPISQADEMERYVRENSNRDEEVNPNKWWENFSEEVKKYYFVFISGSFKGKFEEQLRRLSMTTGVNGSAVNVVNLLLGAEKIRSGEMTIEELERAMFNNSEFILKYGGGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDGSPKKKRKVSS(配列番号17013)を含むか、このアミノ酸配列からなる。あるいは融合タンパク質は、
1 atggcaccaa agaagaaaag aaaagtggag ggcatcaagt caaacatcag cctgctgaaa
61 gacgaactgc ggggacagat tagtcacatc agtcacgagt acctgtcact gattgatctg
121 gccttcgaca gcaagcagaa tagactgttt gagatgaaag tgctggaact gctggtcaac
181 gagtatggct tcaagggcag acatctgggc gggtctagga aacctgacgg catcgtgtac
241 agtaccacac tggaagacaa cttcggaatc attgtcgata ccaaggctta ttccgagggc
301 tactctctgc caattagtca ggcagatgag atggaaaggt acgtgcgcga aaactcaaat
361 agggacgagg aagtcaaccc caataagtgg tgggagaatt tcagcgagga agtgaagaaa
421 tactacttcg tctttatctc aggcagcttc aaagggaagt ttgaggaaca gctgcggaga
481 ctgtccatga ctaccggggt gaacggatct gctgtcaacg tggtcaatct gctgctgggc
541 gcagaaaaga tcaggtccgg ggagatgaca attgaggaac tggaacgcgc catgttcaac
601 aattctgagt ttatcctgaa gtatggaggc gggggaagcg ataagaaata ctccatcgga
661 ctggccattg gcaccaattc cgtgggctgg gctgtcatca cagacgagta caaggtgcca
721 agcaagaagt tcaaggtcct ggggaacacc gatcgccaca gtatcaagaa aaatctgatt
781 ggagccctgc tgttcgactc aggcgagact gctgaagcaa cccgactgaa gcggactgct
841 aggcgccgat atacccggag aaaaaatcgg atctgctacc tgcaggaaat tttcagcaac
901 gagatggcca aggtggacga tagtttcttt caccgcctgg aggaatcatt cctggtggag
961 gaagataaga aacacgagcg gcatcccatc tttggcaaca ttgtggacga agtcgcttat
1021 cacgagaagt accctactat ctatcatctg aggaagaaac tggtggactc caccgataag
1081 gcagacctgc gcctgatcta tctggccctg gctcacatga tcaagttccg ggggcatttt
1141 ctgatcgagg gagatctgaa ccctgacaat tctgatgtgg acaagctgtt catccagctg
1201 gtccagacat acaatcagct gtttgaggaa aacccaatta atgcctcagg cgtggacgca
1261 aaggccatcc tgagcgccag actgtccaaa tctaggcgcc tggaaaacct gatcgctcag
1321 ctgccaggag agaagaaaaa cggcctgttt gggaatctga ttgcactgtc cctgggcctg
1381 acacccaact tcaagtctaa ttttgatctg gccgaggacg ctaagctgca gctgtccaaa
1441 gacacttatg acgatgacct ggataacctg ctggctcaga tcggcgatca gtacgcagac
1501 ctgttcctgg ccgctaagaa tctgagtgac gccatcctgc tgtcagatat tctgcgcgtg
1561 aacacagaga ttactaaggc cccactgagt gcttcaatga tcaaaagata tgacgagcac
1621 catcaggatc tgaccctgct gaaggctctg gtgaggcagc agctgcccga gaaatacaag
1681 gaaatcttct ttgatcagag caagaatgga tacgccggct atattgacgg cggggcttcc
1741 caggaggagt tctacaagtt catcaagccc attctggaaa agatggacgg caccgaggaa
1801 ctgctggtga agctgaatcg ggaggacctg ctgagaaaac agaggacatt tgataacgga
1861 agcatccctc accagattca tctgggcgaa ctgcacgcca tcctgcgacg gcaggaggac
1921 ttctacccat ttctgaagga taaccgcgag aaaatcgaaa agatcctgac cttcagaatc
1981 ccctactatg tggggcctct ggcacgggga aatagtagat ttgcctggat gacaagaaag
2041 tcagaggaaa ctatcacccc ctggaacttc gaggaagtgg tcgataaagg cgctagcgca
2101 cagtccttca ttgaaaggat gacaaatttt gacaagaacc tgccaaatga gaaggtgctg
2161 cccaaacaca gcctgctgta cgaatatttc acagtgtata acgagctgac taaagtgaag
2221 tacgtcaccg aagggatgcg caagcccgca ttcctgtccg gagagcagaa gaaagccatc
2281 gtggacctgc tgtttaagac aaatcggaaa gtgactgtca aacagctgaa ggaagactat
2341 ttcaagaaaa ttgagtgttt cgattcagtg gaaatcagcg gcgtcgagga caggtttaac
2401 gcctccctgg ggacctacca cgatctgctg aagatcatca aggataagga cttcctggac
2461 aacgaggaaa atgaggacat cctggaggac attgtgctga cactgactct gtttgaggat
2521 cgcgaaatga tcgaggaacg actgaagact tatgcccatc tgttcgatga caaagtgatg
2581 aagcagctga aaagaaggcg ctacaccgga tggggacgcc tgagccgaaa actgatcaat
2641 gggattagag acaagcagag cggaaaaact atcctggact ttctgaagtc cgatggcttc
2701 gccaacagga acttcatgca gctgattcac gatgactctc tgaccttcaa ggaggacatc
2761 cagaaagcac aggtgtctgg ccagggggac agtctgcacg agcatatcgc aaacctggcc
2821 ggcagccccg ccatcaagaa agggattctg cagaccgtga aggtggtgga cgaactggtc
2881 aaggtcatgg gacgacacaa acctgagaac atcgtgattg agatggcccg cgaaaatcag
2941 acaactcaga agggccagaa aaacagtcga gaacggatga agagaatcga ggaaggcatc
3001 aaggagctgg ggtcacagat cctgaaggag catcctgtgg aaaacactca gctgcagaat
3061 gagaaactgt atctgtacta tctgcagaat ggacgggata tgtacgtgga ccaggagctg
3121 gatattaaca gactgagtga ttatgacgtg gatgccatcg tccctcagag cttcctgaag
3181 gatgactcca ttgacaacaa ggtgctgacc aggtccgaca agaaccgcgg caaatcagat
3241 aatgtgccaa gcgaggaagt ggtcaagaaa atgaagaact actggaggca gctgctgaat
3301 gccaagctga tcacacagcg gaaatttgat aacctgacta aggcagaaag aggaggcctg
3361 tctgagctgg acaaggccgg cttcatcaag cggcagctgg tggagacaag acagatcact
3421 aagcacgtcg ctcagattct ggatagcaga atgaacacaa agtacgatga aaacgacaag
3481 ctgatcaggg aggtgaaagt cattactctg aaatccaagc tggtgtctga ctttagaaag
3541 gatttccagt tttataaagt cagggagatc aacaactacc accatgctca tgacgcatac
3601 ctgaacgcag tggtcgggac cgccctgatt aagaaatacc ccaagctgga gtccgagttc
3661 gtgtacggag actataaagt gtacgatgtc cggaagatga tcgccaaatc tgagcaggaa
3721 attggcaagg ccaccgctaa gtatttcttt tacagtaaca tcatgaattt ctttaagacc
3781 gaaatcacac tggcaaatgg ggagatcaga aaaaggcctc tgattgagac caacggggag
3841 acaggagaaa tcgtgtggga caagggaagg gattttgcta ccgtgcgcaa agtcctgtcc
3901 atgccccaag tgaatattgt caagaaaact gaagtgcaga ccgggggatt ctctaaggag
3961 agtattctgc ctaagcgaaa ctctgataaa ctgatcgccc ggaagaaaga ctgggacccc
4021 aagaagtatg gcgggttcga ctctccaaca gtggcttaca gtgtcctggt ggtcgcaaag
4081 gtggaaaagg ggaagtccaa gaaactgaag tctgtcaaag agctgctggg aatcactatt
4141 atggaacgca gctccttcga gaagaatcct atcgattttc tggaagccaa gggctataaa
4201 gaggtgaaga aagacctgat cattaagctg ccaaaatact cactgtttga gctggaaaac
4261 ggacgaaagc gaatgctggc aagcgccgga gaactgcaga agggcaatga gctggccctg
4321 ccctccaaat acgtgaactt cctgtatctg gctagccact acgagaaact gaaggggtcc
4381 cctgaggata acgaacagaa gcagctgttt gtggagcagc acaaacatta tctggacgag
4441 atcattgaac agatttcaga gttcagcaag agagtgatcc tggctgacgc aaatctggat
4501 aaagtcctga gcgcatacaa caagcaccga gacaaaccaa tccgggagca ggccgaaaat
4561 atcattcatc tgttcaccct gacaaacctg ggcgcccctg cagccttcaa gtattttgac
4621 accacaatcg atcggaagag atacacttct accaaagagg tgctggatgc taccctgatc
4681 caccagagta ttaccggcct gtatgagaca cgcatcgacc tgtcacagct gggaggcgat
4741 gggagcccca agaaaaagcg gaaggtgtct agttaa(配列番号17014)の配列を含むかこの配列からなる核酸を含むか、この核酸からなる。いくつかの実施態様では、融合タンパク質は、アミノ酸配列:
1 MPKKKRKVEG IKSNISLLKD ELRGQISHIS HEYLSLIDLA FDSKQNRLFE MKVLELLVNE
61 YGFKGRHLGG SRKPDGIVYS TTLEDNFGII VDTKAYSEGY SLPISQADEM ERYVRENSNR
121 DEEVNPNKWW ENFSEEVKKY YFVFISGSFK GKFEEQLRRL SMTTGVNGSA VNVVNLLLGA
181 EKIRSGEMTI EELERAMFNN SEFILKYGGG GSDKKYSIGL AIGTNSVGWA VITDEYKVPS
241 KKFKVLGNTD RHSIKKNLIG ALLFDSGETA EATRLKRTAR RRYTRRKNRI CYLQEIFSNE
301 MAKVDDSFFH RLEESFLVEE DKKHERHPIF GNIVDEVAYH EKYPTIYHLR KKLVDSTDKA
361 DLRLIYLALA HMIKFRGHFL IEGDLNPDNS DVDKLFIQLV QTYNQLFEEN PINASGVDAK
421 AILSARLSKS RRLENLIAQL PGEKKNGLFG NLIALSLGLT PNFKSNFDLA EDAKLQLSKD
481 TYDDDLDNLL AQIGDQYADL FLAAKNLSDA ILLSDILRVN TEITKAPLSA SMIKRYDEHH
541 QDLTLLKALV RQQLPEKYKE IFFDQSKNGY AGYIDGGASQ EEFYKFIKPI LEKMDGTEEL
601 LVKLNREDLL RKQRTFDNGS IPHQIHLGEL HAILRRQEDF YPFLKDNREK IEKILTFRIP
661 YYVGPLARGN SRFAWMTRKS EETITPWNFE EVVDKGASAQ SFIERMTNFD KNLPNEKVLP
721 KHSLLYEYFT VYNELTKVKY VTEGMRKPAF LSGEQKKAIV DLLFKTNRKV TVKQLKEDYF
781 KKIECFDSVE ISGVEDRFNA SLGTYHDLLK IIKDKDFLDN EENEDILEDI VLTLTLFEDR
841 EMIEERLKTY AHLFDDKVMK QLKRRRYTGW GRLSRKLING IRDKQSGKTI LDFLKSDGFA
901 NRNFMQLIHD DSLTFKEDIQ KAQVSGQGDS LHEHIANLAG SPAIKKGILQ TVKVVDELVK
961 VMGRHKPENI VIEMARENQT TQKGQKNSRE RMKRIEEGIK ELGSQILKEH PVENTQLQNE
1021 KLYLYYLQNG RDMYVDQELD INRLSDYDVD AIVPQSFLKD DSIDNKVLTR SDKNRGKSDN
1081 VPSEEVVKKM KNYWRQLLNA KLITQRKFDN LTKAERGGLS ELDKAGFIKR QLVETRQITK
1141 HVAQILDSRM NTKYDENDKL IREVKVITLK SKLVSDFRKD FQFYKVREIN NYHHAHDAYL
1201 NAVVGTALIK KYPKLESEFV YGDYKVYDVR KMIAKSEQEI GKATAKYFFY SNIMNFFKTE
1261 ITLANGEIRK RPLIETNGET GEIVWDKGRD FATVRKVLSM PQVNIVKKTE VQTGGFSKES
1321 ILPKRNSDKL IARKKDWDPK KYGGFDSPTV AYSVLVVAKV EKGKSKKLKS VKELLGITIM
1381 ERSSFEKNPI DFLEAKGYKE VKKDLIIKLP KYSLFELENG RKRMLASAGE LQKGNELALP
1441 SKYVNFLYLA SHYEKLKGSP EDNEQKQLFV EQHKHYLDEI IEQISEFSKR VILADANLDK
1501 VLSAYNKHRD KPIREQAENI IHLFTLTNLG APAAFKYFDT TIDRKRYTST KEVLDATLIH
1561 QSITGLYETR IDLSQLGGDG SPKKKRKV(配列番号17058)を含むか、このアミノ酸配列からなる。あるいは融合タンパク質は、
1 atgcctaaga agaagcggaa ggtggaaggc atcaaaagca acatctccct cctgaaagac
61 gaactccggg ggcagattag ccacattagt cacgaatacc tctccctcat cgacctggct
121 ttcgatagca agcagaacag gctctttgag atgaaagtgc tggaactgct cgtcaatgag
181 tacgggttca agggtcgaca cctcggcgga tctaggaaac cagacggcat cgtgtatagt
241 accacactgg aagacaactt tgggatcatt gtggatacca aggcatactc tgagggttat
301 agtctgccca tttcacaggc cgacgagatg gaacggtacg tgcgcgagaa ctcaaataga
361 gatgaggaag tcaaccctaa caagtggtgg gagaacttct ctgaggaagt gaagaaatac
421 tacttcgtct ttatcagcgg gtccttcaag ggtaaatttg aggaacagct caggagactg
481 agcatgacta ccggcgtgaa tggcagcgcc gtcaacgtgg tcaatctgct cctgggcgct
541 gaaaagattc ggagcggaga gatgaccatc gaagagctgg agagggcaat gtttaataat
601 agcgagttta tcctgaaata cggtggcggt ggatccgata aaaagtattc tattggttta
661 gccatcggca ctaattccgt tggatgggct gtcataaccg atgaatacaa agtaccttca
721 aagaaattta aggtgttggg gaacacagac cgtcattcga ttaaaaagaa tcttatcggt
781 gccctcctat tcgatagtgg cgaaacggca gaggcgactc gcctgaaacg aaccgctcgg
841 agaaggtata cacgtcgcaa gaaccgaata tgttacttac aagaaatttt tagcaatgag
901 atggccaaag ttgacgattc tttctttcac cgtttggaag agtccttcct tgtcgaagag
961 gacaagaaac atgaacggca ccccatcttt ggaaacatag tagatgaggt ggcatatcat
1021 gaaaagtacc caacgattta tcacctcaga aaaaagctag ttgactcaac tgataaagcg
1081 gacctgaggt taatctactt ggctcttgcc catatgataa agttccgtgg gcactttctc
1141 attgagggtg atctaaatcc ggacaactcg gatgtcgaca aactgttcat ccagttagta
1201 caaacctata atcagttgtt tgaagagaac cctataaatg caagtggcgt ggatgcgaag
1261 gctattctta gcgcccgcct ctctaaatcc cgacggctag aaaacctgat cgcacaatta
1321 cccggagaga agaaaaatgg gttgttcggt aaccttatag cgctctcact aggcctgaca
1381 ccaaatttta agtcgaactt cgacttagct gaagatgcca aattgcagct tagtaaggac
1441 acgtacgatg acgatctcga caatctactg gcacaaattg gagatcagta tgcggactta
1501 tttttggctg ccaaaaacct tagcgatgca atcctcctat ctgacatact gagagttaat
1561 actgagatta ccaaggcgcc gttatccgct tcaatgatca aaaggtacga tgaacatcac
1621 caagacttga cacttctcaa ggccctagtc cgtcagcaac tgcctgagaa atataaggaa
1681 atattctttg atcagtcgaa aaacgggtac gcaggttata ttgacggcgg agcgagtcaa
1741 gaggaattct acaagtttat caaacccata ttagagaaga tggatgggac ggaagagttg
1801 cttgtaaaac tcaatcgcga agatctactg cgaaagcagc ggactttcga caacggtagc
1861 attccacatc aaatccactt aggcgaattg catgctatac ttagaaggca ggaggatttt
1921 tatccgttcc tcaaagacaa tcgtgaaaag attgagaaaa tcctaacctt tcgcatacct
1981 tactatgtgg gacccctggc ccgagggaac tctcggttcg catggatgac aagaaagtcc
2041 gaagaaacga ttactccatg gaattttgag gaagttgtcg ataaaggtgc gtcagctcaa
2101 tcgttcatcg agaggatgac caactttgac aagaatttac cgaacgaaaa agtattgcct
2161 aagcacagtt tactttacga gtatttcaca gtgtacaatg aactcacgaa agttaagtat
2221 gtcactgagg gcatgcgtaa acccgccttt ctaagcggag aacagaagaa agcaatagta
2281 gatctgttat tcaagaccaa ccgcaaagtg acagttaagc aattgaaaga ggactacttt
2341 aagaaaattg aatgcttcga ttctgtcgag atctccgggg tagaagatcg atttaatgcg
2401 tcacttggta cgtatcatga cctcctaaag ataattaaag ataaggactt cctggataac
2461 gaagagaatg aagatatctt agaagatata gtgttgactc ttaccctctt tgaagatcgg
2521 gaaatgattg aggaaagact aaaaacatac gctcacctgt tcgacgataa ggttatgaaa
2581 cagttaaaga ggcgtcgcta tacgggctgg ggacgattgt cgcggaaact tatcaacggg
2641 ataagagaca agcaaagtgg taaaactatt ctcgattttc taaagagcga cggcttcgcc
2701 aataggaact ttatgcagct gatccatgat gactctttaa ccttcaaaga ggatatacaa
2761 aaggcacagg tttccggaca aggggactca ttgcacgaac atattgcgaa tcttgctggt
2821 tcgccagcca tcaaaaaggg catactccag acagtcaaag tagtggatga gctagttaag
2881 gtcatgggac gtcacaaacc ggaaaacatt gtaatcgaga tggcacgcga aaatcaaacg
2941 actcagaagg ggcaaaaaaa cagtcgagag cggatgaaga gaatagaaga gggtattaaa
3001 gaactgggca gccagatctt aaaggagcat cctgtggaaa atacccaatt gcagaacgag
3061 aaactttacc tctattacct acaaaatgga agggacatgt atgttgatca ggaactggac
3121 ataaaccgtt tatctgatta cgacgtcgat gccattgtac cccaatcctt tttgaaggac
3181 gattcaatcg acaataaagt gcttacacgc tcggataaga accgagggaa aagtgacaat
3241 gttccaagcg aggaagtcgt aaagaaaatg aagaactatt ggcggcagct cctaaatgcg
3301 aaactgataa cgcaaagaaa gttcgataac ttaactaaag ctgagagggg tggcttgtct
3361 gaacttgaca aggccggatt tattaaacgt cagctcgtgg aaacccgcca aatcacaaag
3421 catgttgcac agatactaga ttcccgaatg aatacgaaat acgacgagaa cgataagctg
3481 attcgggaag tcaaagtaat cactttaaag tcaaaattgg tgtcggactt cagaaaggat
3541 tttcaattct ataaagttag ggagataaat aactaccacc atgcgcacga cgcttatctt
3601 aatgccgtcg tagggaccgc actcattaag aaatacccga agctagaaag tgagtttgtg
3661 tatggtgatt acaaagttta tgacgtccgt aagatgatcg cgaaaagcga acaggagata
3721 ggcaaggcta cagccaaata cttcttttat tctaacatta tgaatttctt taagacggaa
3781 atcactctgg caaacggaga gatacgcaaa cgacctttaa ttgaaaccaa tggggagaca
3841 ggtgaaatcg tatgggataa gggccgggac ttcgcgacgg tgagaaaagt tttgtccatg
3901 ccccaagtca acatagtaaa gaaaactgag gtgcagaccg gagggttttc aaaggaatcg
3961 attcttccaa aaaggaatag tgataagctc atcgctcgta aaaaggactg ggacccgaaa
4021 aagtacggtg gcttcgatag ccctacagtt gcctattctg tcctagtagt ggcaaaagtt
4081 gagaagggaa aatccaagaa actgaagtca gtcaaagaat tattggggat aacgattatg
4141 gagcgctcgt cttttgaaaa gaaccccatc gacttccttg aggcgaaagg ttacaaggaa
4201 gtaaaaaagg atctcataat taaactacca aagtatagtc tgtttgagtt agaaaatggc
4261 cgaaaacgga tgttggctag cgccggagag cttcaaaagg ggaacgaact cgcactaccg
4321 tctaaatacg tgaatttcct gtatttagcg tcccattacg agaagttgaa aggttcacct
4381 gaagataacg aacagaagca actttttgtt gagcagcaca aacattatct cgacgaaatc
4441 atagagcaaa tttcggaatt cagtaagaga gtcatcctag ctgatgccaa tctggacaaa
4501 gtattaagcg catacaacaa gcacagggat aaacccatac gtgagcaggc ggaaaatatt
4561 atccatttgt ttactcttac caacctcggc gctccagccg cattcaagta ttttgacaca
4621 acgatagatc gcaaacgata cacttctacc aaggaggtgc tagacgcgac actgattcac
4681 caatccatca cgggattata tgaaactcgg atagatttgt cacagcttgg gggtgacgga
4741 tcccccaaga agaagaggaa agtctga(配列番号17059)の配列を含むかこの配列からなる核酸を含むか、この核酸からなる。
ベクターと宿主細胞
tgtacatagattaaccctagaaagataatcatattgtgacgtacgttaaagataatcatgcgtaaaattgacgcatgtgttttatcggtctgtatatcgaggtttatttattaatttgaatagatattaagttttattatatttacacttacatactaataataaattcaacaaacaatttatttatgtttatttatttattaaaaaaaaacaaaaactcaaaatttcttctataaagtaacaaaacttttatcgaatacctgcagcccgggggatgcagagggacagcccccccccaaagcccccagggatgtaattacgtccctcccccgctagggggcagcagcgagccgcccggggctccgctccggtccggcgctccccccgcatccccgagccggcagcgtgcggggacagcccgggcacggggaaggtggcacgggatcgctttcctctgaacgcttctcgctgctctttgagcctgcagacacctggggggatacggggaaaagttgactgtgcctttcgatcgaaccatggacagttagctttgcaaagatggataaagttttaaacagagaggaatctttgcagctaatggaccttctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgaaccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacacaggtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcgtgccttgaattacttccacctggctgcagtacgtgattcttgatcccgagcttcgggttggaagtgggtgggagagttcgaggccttgcgcttaaggagccccttcgcctcgtgcttgagttgaggcctggcctgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcctgtctcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttctggcaagatagtcttgtaaatgcgggccaagatctgcacactggtatttcggtttttggggccgcgggcggcgacggggcccgtgcgtcccagcgcacatgttcggcgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggccggcctgctctggtgcctggcctcgcgccgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcaccagttgcgtgagcggaaagatggccgcttcccggccctgctgcagggagctcaaaatggaggacgcggcgctcgggagagcgggcgggtgagtcacccacacaaaggaaaagggcctttccgtcctcagccgtcgcttcatgtgactccacggagtaccgggcgccgtccaggcacctcgattagttctcgagcttttggagtacgtcgtctttaggttggggggaggggttttatgcgatggagtttccccacactgagtgggtggagactgaagttaggccagcttggcacttgatgtaattctccttggaatttgccctttttgagtttggatcttggttcattctcaagcctcagacagtggttcaaagtttttttcttccatttcaggtgtcgtgagaattctaatacgactcactatagggtgtgctgtctcatcattttggcaaagattggccaccaagcttgtcctgcaggagggtcgacgcctctagacgggcggccgctccggatccacgggtaccgatcacatatgcctttaattaaacactagttctatagtgtcacctaaattccctttagtgagggttaatggccgtaggccgccagaattgggtccagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcattttatgtttcaggttcagggggaggtgtgggaggttttttcggactctaggacctgcgcatgcgcttggcgtaatcatggtcatagctgtttcctgttttccccgtatccccccaggtgtctgcaggctcaaagagcagcgagaagcgttcagaggaaagcgatcccgtgccaccttccccgtgcccgggctgtccccgcacgctgccggctcggggatgcggggggagcgccggaccggagcggagccccgggcggctcgctgctgccccctagcgggggagggacgtaattacatccctgggggctttgggggggggctgtccctctcaccgcggtggagctccagcttttgttcgaattggggccccccctcgagggtatcgatgatatctataacaagaaaatatatatataataagttatcacgtaagtagaacatgaaataacaatataattatcgtatgagttaaatcttaaaagtcacgtaaaagataatcatgcgtcattttgactcacgcggtcgttatagttcaaaatcagtgacacttaccgcattgacaagcacgcctcacgggagctccaagcggcgactgagatgtcctaaatgcacagcgacggattcgcgctatttagaaagagagagcaatatttcaagaatgcatgcgtcaattttacgcagactatctttctagggttaatctagctagccttaagggcgcctattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagtcagaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggagcggcgataccgtaaagcacgaggaagcggtcagcccattcgccgccaagctcttcagcaatatcacgggtagccaacgctatgtcctgatagcggtccgccacacccagccggccacagtcgatgaatccagaaaagcggccattttccaccatgatattcggcaagcaggcatcgccatgggtcacgacgagatcctcgccgtcgggcatgctcgccttgagcctggcgaacagttcggctggcgcgagcccctgatgctcttcgtccagatcatcctgatcgacaagaccggcttccatccgagtacgtgctcgctcgatgcgatgtttcgcttggtggtcgaatgggcaggtagccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgcccaatagcagccagtcccttcccgcttcagtgacaacgtcgagcacagctgcgcaaggaacgcccgtcgtggccagccacgatagccgcgctgcctcgtcttgcagttcattcagggcaccggacaggtcggtcttgacaaaaagaaccgggcgcccctgcgctgacagccggaacacggcggcatcagagcagccgattgtctgttgtgcccagtcatagccgaatagcctctccacccaagcggccggagaacctgcgtgcaatccatcttgttcaatcataatattattgaagcatttatcagggttcgtctcgtcccggtctcctcccaatgcatgtcaatattggccattagccatattattcattggttatatagcataaatcaatattggctattggccattgcatacgttgtatctatatcataata(配列番号18051)を含んでいる。
CARTyrinの精製
アミノ酸コード
治療活性な成分をさらに含むCARTyrin組成物
白血球除去産物からのT細胞単離
自己由来T細胞産物組成物の遺伝子改変
自己由来のT細胞産物組成物の遺伝子改変
出荷するための遺伝子改変された自己由来T細胞の分析
細胞産物の輸液および/または輸液のための低温保存
製剤
治療への応用
代替投与
非経口製剤と投与
代替送達
養子細胞療法としての改変された細胞の輸液
誘導性アポトーシス促進ポリペプチド
武装化T細胞「ノックダウン」戦略
武装化T細胞「合成遺伝子発現」戦略
外来性受容体
YIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(配列番号18011)を含むアミノ酸配列を含んでいる。いくつかの実施態様では、4-1BB共刺激ドメインは、aagagaggcaggaagaaactgctgtatattttcaaacagcccttcatgcgccccgtgcagactacccaggaggaagacgggtgctcctgtcgattccctgaggaagaggaaggcgggtgtgagctg(配列番号18013)を含む核酸配列によってコードされている。いくつかの実施態様では、4-1BB共刺激ドメインは、膜貫通ドメインとCD28共刺激ドメインの間に位置する。
誘導性プロモータ
誘導性導入遺伝子
小さなCas9(SaCas9)
1 mkrnyilgld igitsvgygi idyetrdvid agvrlfkean vennegrrsk rgarrlkrrr
61 rhriqrvkkl lfdynlltdh selsginpye arvkglsqkl seeefsaall hlakrrgvhn
121 vneveedtgn elstkeqisr nskaleekyv aelqlerlkk dgevrgsinr fktsdyvkea
181 kqllkvqkay hqldqsfidt yidlletrrt yyegpgegsp fgwkdikewy emlmghctyf
241 peelrsvkya ynadlynaln dlnnlvitrd enekleyyek fqiienvfkq kkkptlkqia
301 keilvneedi kgyrvtstgk peftnlkvyh dikditarke iienaelldq iakiltiyqs
361 sediqeeltn lnseltqeei eqisnlkgyt gthnlslkai nlildelwht ndnqiaifnr
421 lklvpkkvdl sqqkeipttl vddfilspvv krsfiqsikv inaiikkygl pndiiielar
481 eknskdaqkm inemqkrnrq tnerieeiir ttgkenakyl iekiklhdmq egkclyslea
541 ipledllnnp fnyevdhiip rsvsfdnsfn nkvlvkqeen skkgnrtpfq ylsssdskis
601 yetfkkhiln lakgkgrisk tkkeylleer dinrfsvqkd finrnlvdtr yatrglmnll
661 rsyfrvnnld vkvksinggf tsflrrkwkf kkernkgykh haedaliian adfifkewkk
721 ldkakkvmen qmfeekqaes mpeieteqey keifitphqi khikdfkdyk yshrvdkkpn
781 relindtlys trkddkgntl ivnnlnglyd kdndklkkli nkspekllmy hhdpqtyqkl
841 klimeqygde knplykyyee tgnyltkysk kdngpvikki kyygnklnah lditddypns
901 rnkvvklslk pyrfdvyldn gvykfvtvkn ldvikkenyy evnskcyeea kklkkisnqa
961 efiasfynnd likingelyr vigvnndlln rievnmidit yreylenmnd krppriikti
1021 asktqsikky stdilgnlye vkskkhpqii kkg(配列番号18052)。
不活性化された小さなCas9(dSaCas9)
IDLAFDSKQNRLFEMKVLELLVNEYGFKGRHLGGSRKPDGIVYSTTLEDNFGIIVDTKAYSEGYSLPISQADEMERYVRENSNRDEEVNPNKWWENFSEEVKKYYFVFISGSFKGKFEEQLRRLSMTTGVNGSAVNVVNLLLGAEKIRSGEMTIEELERAMFNNSEFILKY(配列番号18056)のアミノ酸配列を含むか、主にこのアミノ酸配列からなるか、このアミノ酸配列からなることができる。
Cas-Clover融合タンパク質
1 atggcaccaa agaagaaaag aaaagtggag ggcatcaagt caaacatcag cctgctgaaa
61 gacgaactgc ggggacagat tagtcacatc agtcacgagt acctgtcact gattgatctg
121 gccttcgaca gcaagcagaa tagactgttt gagatgaaag tgctggaact gctggtcaac
181 gagtatggct tcaagggcag acatctgggc gggtctagga aacctgacgg catcgtgtac
241 agtaccacac tggaagacaa cttcggaatc attgtcgata ccaaggctta ttccgagggc
301 tactctctgc caattagtca ggcagatgag atggaaaggt acgtgcgcga aaactcaaat
361 agggacgagg aagtcaaccc caataagtgg tgggagaatt tcagcgagga agtgaagaaa
421 tactacttcg tctttatctc aggcagcttc aaagggaagt ttgaggaaca gctgcggaga
481 ctgtccatga ctaccggggt gaacggatct gctgtcaacg tggtcaatct gctgctgggc
541 gcagaaaaga tcaggtccgg ggagatgaca attgaggaac tggaacgcgc catgttcaac
601 aattctgagt ttatcctgaa gtatggaggc gggggaagcg ataagaaata ctccatcgga
661 ctggccattg gcaccaattc cgtgggctgg gctgtcatca cagacgagta caaggtgcca
721 agcaagaagt tcaaggtcct ggggaacacc gatcgccaca gtatcaagaa aaatctgatt
781 ggagccctgc tgttcgactc aggcgagact gctgaagcaa cccgactgaa gcggactgct
841 aggcgccgat atacccggag aaaaaatcgg atctgctacc tgcaggaaat tttcagcaac
901 gagatggcca aggtggacga tagtttcttt caccgcctgg aggaatcatt cctggtggag
961 gaagataaga aacacgagcg gcatcccatc tttggcaaca ttgtggacga agtcgcttat
1021 cacgagaagt accctactat ctatcatctg aggaagaaac tggtggactc caccgataag
1081 gcagacctgc gcctgatcta tctggccctg gctcacatga tcaagttccg ggggcatttt
1141 ctgatcgagg gagatctgaa ccctgacaat tctgatgtgg acaagctgtt catccagctg
1201 gtccagacat acaatcagct gtttgaggaa aacccaatta atgcctcagg cgtggacgca
1261 aaggccatcc tgagcgccag actgtccaaa tctaggcgcc tggaaaacct gatcgctcag
1321 ctgccaggag agaagaaaaa cggcctgttt gggaatctga ttgcactgtc cctgggcctg
1381 acacccaact tcaagtctaa ttttgatctg gccgaggacg ctaagctgca gctgtccaaa
1441 gacacttatg acgatgacct ggataacctg ctggctcaga tcggcgatca gtacgcagac
1501 ctgttcctgg ccgctaagaa tctgagtgac gccatcctgc tgtcagatat tctgcgcgtg
1561 aacacagaga ttactaaggc cccactgagt gcttcaatga tcaaaagata tgacgagcac
1621 catcaggatc tgaccctgct gaaggctctg gtgaggcagc agctgcccga gaaatacaag
1681 gaaatcttct ttgatcagag caagaatgga tacgccggct atattgacgg cggggcttcc
1741 caggaggagt tctacaagtt catcaagccc attctggaaa agatggacgg caccgaggaa
1801 ctgctggtga agctgaatcg ggaggacctg ctgagaaaac agaggacatt tgataacgga
1861 agcatccctc accagattca tctgggcgaa ctgcacgcca tcctgcgacg gcaggaggac
1921 ttctacccat ttctgaagga taaccgcgag aaaatcgaaa agatcctgac cttcagaatc
1981 ccctactatg tggggcctct ggcacgggga aatagtagat ttgcctggat gacaagaaag
2041 tcagaggaaa ctatcacccc ctggaacttc gaggaagtgg tcgataaagg cgctagcgca
2101 cagtccttca ttgaaaggat gacaaatttt gacaagaacc tgccaaatga gaaggtgctg
2161 cccaaacaca gcctgctgta cgaatatttc acagtgtata acgagctgac taaagtgaag
2221 tacgtcaccg aagggatgcg caagcccgca ttcctgtccg gagagcagaa gaaagccatc
2281 gtggacctgc tgtttaagac aaatcggaaa gtgactgtca aacagctgaa ggaagactat
2341 ttcaagaaaa ttgagtgttt cgattcagtg gaaatcagcg gcgtcgagga caggtttaac
2401 gcctccctgg ggacctacca cgatctgctg aagatcatca aggataagga cttcctggac
2461 aacgaggaaa atgaggacat cctggaggac attgtgctga cactgactct gtttgaggat
2521 cgcgaaatga tcgaggaacg actgaagact tatgcccatc tgttcgatga caaagtgatg
2581 aagcagctga aaagaaggcg ctacaccgga tggggacgcc tgagccgaaa actgatcaat
2641 gggattagag acaagcagag cggaaaaact atcctggact ttctgaagtc cgatggcttc
2701 gccaacagga acttcatgca gctgattcac gatgactctc tgaccttcaa ggaggacatc
2761 cagaaagcac aggtgtctgg ccagggggac agtctgcacg agcatatcgc aaacctggcc
2821 ggcagccccg ccatcaagaa agggattctg cagaccgtga aggtggtgga cgaactggtc
2881 aaggtcatgg gacgacacaa acctgagaac atcgtgattg agatggcccg cgaaaatcag
2941 acaactcaga agggccagaa aaacagtcga gaacggatga agagaatcga ggaaggcatc
3001 aaggagctgg ggtcacagat cctgaaggag catcctgtgg aaaacactca gctgcagaat
3061 gagaaactgt atctgtacta tctgcagaat ggacgggata tgtacgtgga ccaggagctg
3121 gatattaaca gactgagtga ttatgacgtg gatgccatcg tccctcagag cttcctgaag
3181 gatgactcca ttgacaacaa ggtgctgacc aggtccgaca agaaccgcgg caaatcagat
3241 aatgtgccaa gcgaggaagt ggtcaagaaa atgaagaact actggaggca gctgctgaat
3301 gccaagctga tcacacagcg gaaatttgat aacctgacta aggcagaaag aggaggcctg
3361 tctgagctgg acaaggccgg cttcatcaag cggcagctgg tggagacaag acagatcact
3421 aagcacgtcg ctcagattct ggatagcaga atgaacacaa agtacgatga aaacgacaag
3481 ctgatcaggg aggtgaaagt cattactctg aaatccaagc tggtgtctga ctttagaaag
3541 gatttccagt tttataaagt cagggagatc aacaactacc accatgctca tgacgcatac
3601 ctgaacgcag tggtcgggac cgccctgatt aagaaatacc ccaagctgga gtccgagttc
3661 gtgtacggag actataaagt gtacgatgtc cggaagatga tcgccaaatc tgagcaggaa
3721 attggcaagg ccaccgctaa gtatttcttt tacagtaaca tcatgaattt ctttaagacc
3781 gaaatcacac tggcaaatgg ggagatcaga aaaaggcctc tgattgagac caacggggag
3841 acaggagaaa tcgtgtggga caagggaagg gattttgcta ccgtgcgcaa agtcctgtcc
3901 atgccccaag tgaatattgt caagaaaact gaagtgcaga ccgggggatt ctctaaggag
3961 agtattctgc ctaagcgaaa ctctgataaa ctgatcgccc ggaagaaaga ctgggacccc
4021 aagaagtatg gcgggttcga ctctccaaca gtggcttaca gtgtcctggt ggtcgcaaag
4081 gtggaaaagg ggaagtccaa gaaactgaag tctgtcaaag agctgctggg aatcactatt
4141 atggaacgca gctccttcga gaagaatcct atcgattttc tggaagccaa gggctataaa
4201 gaggtgaaga aagacctgat cattaagctg ccaaaatact cactgtttga gctggaaaac
4261 ggacgaaagc gaatgctggc aagcgccgga gaactgcaga agggcaatga gctggccctg
4321 ccctccaaat acgtgaactt cctgtatctg gctagccact acgagaaact gaaggggtcc
4381 cctgaggata acgaacagaa gcagctgttt gtggagcagc acaaacatta tctggacgag
4441 atcattgaac agatttcaga gttcagcaag agagtgatcc tggctgacgc aaatctggat
4501 aaagtcctga gcgcatacaa caagcaccga gacaaaccaa tccgggagca ggccgaaaat
4561 atcattcatc tgttcaccct gacaaacctg ggcgcccctg cagccttcaa gtattttgac
4621 accacaatcg atcggaagag atacacttct accaaagagg tgctggatgc taccctgatc
4681 caccagagta ttaccggcct gtatgagaca cgcatcgacc tgtcacagct gggaggcgat
4741 gggagcccca agaaaaagcg gaaggtgtct agttaa(配列番号18058)の核酸配列(化膿性ブドウ球菌に由来するdCas9配列)を含むか、主にこの核酸配列からなるか、この核酸配列からなることができる。
1 atgcctaaga agaagcggaa ggtggaaggc atcaaaagca acatctccct cctgaaagac
61 gaactccggg ggcagattag ccacattagt cacgaatacc tctccctcat cgacctggct
121 ttcgatagca agcagaacag gctctttgag atgaaagtgc tggaactgct cgtcaatgag
181 tacgggttca agggtcgaca cctcggcgga tctaggaaac cagacggcat cgtgtatagt
241 accacactgg aagacaactt tgggatcatt gtggatacca aggcatactc tgagggttat
301 agtctgccca tttcacaggc cgacgagatg gaacggtacg tgcgcgagaa ctcaaataga
361 gatgaggaag tcaaccctaa caagtggtgg gagaacttct ctgaggaagt gaagaaatac
421 tacttcgtct ttatcagcgg gtccttcaag ggtaaatttg aggaacagct caggagactg
481 agcatgacta ccggcgtgaa tggcagcgcc gtcaacgtgg tcaatctgct cctgggcgct
541 gaaaagattc ggagcggaga gatgaccatc gaagagctgg agagggcaat gtttaataat
601 agcgagttta tcctgaaata cggtggcggt ggatccgata aaaagtattc tattggttta
661 gccatcggca ctaattccgt tggatgggct gtcataaccg atgaatacaa agtaccttca
721 aagaaattta aggtgttggg gaacacagac cgtcattcga ttaaaaagaa tcttatcggt
781 gccctcctat tcgatagtgg cgaaacggca gaggcgactc gcctgaaacg aaccgctcgg
841 agaaggtata cacgtcgcaa gaaccgaata tgttacttac aagaaatttt tagcaatgag
901 atggccaaag ttgacgattc tttctttcac cgtttggaag agtccttcct tgtcgaagag
961 gacaagaaac atgaacggca ccccatcttt ggaaacatag tagatgaggt ggcatatcat
1021 gaaaagtacc caacgattta tcacctcaga aaaaagctag ttgactcaac tgataaagcg
1081 gacctgaggt taatctactt ggctcttgcc catatgataa agttccgtgg gcactttctc
1141 attgagggtg atctaaatcc ggacaactcg gatgtcgaca aactgttcat ccagttagta
1201 caaacctata atcagttgtt tgaagagaac cctataaatg caagtggcgt ggatgcgaag
1261 gctattctta gcgcccgcct ctctaaatcc cgacggctag aaaacctgat cgcacaatta
1321 cccggagaga agaaaaatgg gttgttcggt aaccttatag cgctctcact aggcctgaca
1381 ccaaatttta agtcgaactt cgacttagct gaagatgcca aattgcagct tagtaaggac
1441 acgtacgatg acgatctcga caatctactg gcacaaattg gagatcagta tgcggactta
1501 tttttggctg ccaaaaacct tagcgatgca atcctcctat ctgacatact gagagttaat
1561 actgagatta ccaaggcgcc gttatccgct tcaatgatca aaaggtacga tgaacatcac
1621 caagacttga cacttctcaa ggccctagtc cgtcagcaac tgcctgagaa atataaggaa
1681 atattctttg atcagtcgaa aaacgggtac gcaggttata ttgacggcgg agcgagtcaa
1741 gaggaattct acaagtttat caaacccata ttagagaaga tggatgggac ggaagagttg
1801 cttgtaaaac tcaatcgcga agatctactg cgaaagcagc ggactttcga caacggtagc
1861 attccacatc aaatccactt aggcgaattg catgctatac ttagaaggca ggaggatttt
1921 tatccgttcc tcaaagacaa tcgtgaaaag attgagaaaa tcctaacctt tcgcatacct
1981 tactatgtgg gacccctggc ccgagggaac tctcggttcg catggatgac aagaaagtcc
2041 gaagaaacga ttactccatg gaattttgag gaagttgtcg ataaaggtgc gtcagctcaa
2101 tcgttcatcg agaggatgac caactttgac aagaatttac cgaacgaaaa agtattgcct
2161 aagcacagtt tactttacga gtatttcaca gtgtacaatg aactcacgaa agttaagtat
2221 gtcactgagg gcatgcgtaa acccgccttt ctaagcggag aacagaagaa agcaatagta
2281 gatctgttat tcaagaccaa ccgcaaagtg acagttaagc aattgaaaga ggactacttt
2341 aagaaaattg aatgcttcga ttctgtcgag atctccgggg tagaagatcg atttaatgcg
2401 tcacttggta cgtatcatga cctcctaaag ataattaaag ataaggactt cctggataac
2461 gaagagaatg aagatatctt agaagatata gtgttgactc ttaccctctt tgaagatcgg
2521 gaaatgattg aggaaagact aaaaacatac gctcacctgt tcgacgataa ggttatgaaa
2581 cagttaaaga ggcgtcgcta tacgggctgg ggacgattgt cgcggaaact tatcaacggg
2641 ataagagaca agcaaagtgg taaaactatt ctcgattttc taaagagcga cggcttcgcc
2701 aataggaact ttatgcagct gatccatgat gactctttaa ccttcaaaga ggatatacaa
2761 aaggcacagg tttccggaca aggggactca ttgcacgaac atattgcgaa tcttgctggt
2821 tcgccagcca tcaaaaaggg catactccag acagtcaaag tagtggatga gctagttaag
2881 gtcatgggac gtcacaaacc ggaaaacatt gtaatcgaga tggcacgcga aaatcaaacg
2941 actcagaagg ggcaaaaaaa cagtcgagag cggatgaaga gaatagaaga gggtattaaa
3001 gaactgggca gccagatctt aaaggagcat cctgtggaaa atacccaatt gcagaacgag
3061 aaactttacc tctattacct acaaaatgga agggacatgt atgttgatca ggaactggac
3121 ataaaccgtt tatctgatta cgacgtcgat gccattgtac cccaatcctt tttgaaggac
3181 gattcaatcg acaataaagt gcttacacgc tcggataaga accgagggaa aagtgacaat
3241 gttccaagcg aggaagtcgt aaagaaaatg aagaactatt ggcggcagct cctaaatgcg
3301 aaactgataa cgcaaagaaa gttcgataac ttaactaaag ctgagagggg tggcttgtct
3361 gaacttgaca aggccggatt tattaaacgt cagctcgtgg aaacccgcca aatcacaaag
3421 catgttgcac agatactaga ttcccgaatg aatacgaaat acgacgagaa cgataagctg
3481 attcgggaag tcaaagtaat cactttaaag tcaaaattgg tgtcggactt cagaaaggat
3541 tttcaattct ataaagttag ggagataaat aactaccacc atgcgcacga cgcttatctt
3601 aatgccgtcg tagggaccgc actcattaag aaatacccga agctagaaag tgagtttgtg
3661 tatggtgatt acaaagttta tgacgtccgt aagatgatcg cgaaaagcga acaggagata
3721 ggcaaggcta cagccaaata cttcttttat tctaacatta tgaatttctt taagacggaa
3781 atcactctgg caaacggaga gatacgcaaa cgacctttaa ttgaaaccaa tggggagaca
3841 ggtgaaatcg tatgggataa gggccgggac ttcgcgacgg tgagaaaagt tttgtccatg
3901 ccccaagtca acatagtaaa gaaaactgag gtgcagaccg gagggttttc aaaggaatcg
3961 attcttccaa aaaggaatag tgataagctc atcgctcgta aaaaggactg ggacccgaaa
4021 aagtacggtg gcttcgatag ccctacagtt gcctattctg tcctagtagt ggcaaaagtt
4081 gagaagggaa aatccaagaa actgaagtca gtcaaagaat tattggggat aacgattatg
4141 gagcgctcgt cttttgaaaa gaaccccatc gacttccttg aggcgaaagg ttacaaggaa
4201 gtaaaaaagg atctcataat taaactacca aagtatagtc tgtttgagtt agaaaatggc
4261 cgaaaacgga tgttggctag cgccggagag cttcaaaagg ggaacgaact cgcactaccg
4321 tctaaatacg tgaatttcct gtatttagcg tcccattacg agaagttgaa aggttcacct
4381 gaagataacg aacagaagca actttttgtt gagcagcaca aacattatct cgacgaaatc
4441 atagagcaaa tttcggaatt cagtaagaga gtcatcctag ctgatgccaa tctggacaaa
4501 gtattaagcg catacaacaa gcacagggat aaacccatac gtgagcaggc ggaaaatatt
4561 atccatttgt ttactcttac caacctcggc gctccagccg cattcaagta ttttgacaca
4621 acgatagatc gcaaacgata cacttctacc aaggaggtgc tagacgcgac actgattcac
4681 caatccatca cgggattata tgaaactcgg atagatttgt cacagcttgg gggtgacgga
4741 tcccccaaga agaagaggaa agtctga(配列番号18060)の核酸配列(化膿性ブドウ球菌に由来するdCas9配列)を含むか、主にこの核酸配列からなるか、この核酸配列からなることができる。
PSMA5 CARTyrinとPSMA8 CARTyrinを図1、図2、図3A~図3C、図4A~図4Cに示したようにして構成した。図5は、抗PSMA CARTyrinの構造を示している。
実施例2:マウス異種移植片モデルを用いたPSMA5 CARTyrinとPSMA8 CARTyrinの生体内特徴付け
実施例3:組み込まれたiC9安全スイッチを含むpiggyBacのヒト汎T細胞における発現と機能
実施例4:武装化T細胞上のチェックポイントシグナル伝達タンパク質のノックダウン効率
実施例5:武装化T細胞上でヌル細胞内シグナル伝達タンパク質またはスイッチ細胞内シグナル伝達タンパク質を発現させるための戦略
実施例6:武装化T細胞上でのPD1とTGFβRIIのヌル細胞内シグナル伝達タンパク質とスイッチ細胞内シグナル伝達タンパク質の表面発現を増強する
実施例7:改変されたT細胞の中で発現させるためのNF-KB誘導性ベクターの設計
実施例8:改変されたT細胞の中でGFPを発現させるためのNF-KB誘導性ベクター
実施例9:改変されたT細胞の中で抗BCMA CARを媒介としてGFPを発現させるためのNF-KB誘導性ベクター
実施例10:改変されたT細胞における抗BCMA CARを媒介とした発現の制御
参照による組み込み
他の実施態様
Claims (33)
- (a)前立腺特異的膜抗原(PSMA)に特異的に結合する少なくとも1つのセンチリンを含む抗原認識領域を含むエクトドメインと;
(b)膜貫通ドメインと;
(c)少なくとも1つの共刺激ドメインを含むエンドドメイン
を含み、
PSMAに特異的に結合する前記少なくとも1つのセンチリンが、配列番号18002のアミノ酸配列を含む、キメラ抗原受容体(CAR)。 - 前記エクトドメインがシグナルペプチドをさらに含む、請求項1に記載のCAR。
- 前記エクトドメインが、前記抗原認識領域と前記膜貫通ドメインの間にヒンジをさらに含む、請求項1に記載のCAR。
- 前記シグナルペプチドが、ヒトのCD2シグナルペプチド、CD3δシグナルペプチド、CD3εシグナルペプチド、CD3γシグナルペプチド、CD3ζシグナルペプチド、CD4シグナルペプチド、CD8αシグナルペプチド、CD19シグナルペプチド、CD28シグナルペプチド、4-1BBシグナルペプチド、GM-CSFRシグナルペプチドのいずれかをコードするアミノ酸配列を含む、請求項2に記載のCAR。
- 前記シグナルペプチドが、ヒトCD8αシグナルペプチドをコードするアミノ酸配列を含む、請求項4に記載のCAR。
- 前記ヒトCD8αシグナルペプチドが、配列番号18004のアミノ酸配列を含む、請求項5に記載のCAR。
- 前記膜貫通ドメインが、ヒトのCD2膜貫通ドメイン、CD3δ膜貫通ドメイン、CD3ε膜貫通ドメイン、CD3γ膜貫通ドメイン、CD3ζ膜貫通ドメイン、CD4膜貫通ドメイン、CD8α膜貫通ドメイン、CD19膜貫通ドメイン、CD28膜貫通ドメイン、4-1BB膜貫通ドメイン、GM-CSFR膜貫通ドメインのいずれかをコードするアミノ酸配列を含む、請求項1に記載のCAR。
- 前記膜貫通ドメインが、ヒトCD8α膜貫通ドメインをコードするアミノ酸配列を含む、請求項7に記載のCAR。
- 前記ヒトCD8α膜貫通ドメインが、配列番号18006のアミノ酸配列を含む、請求項8に記載のCAR。
- 前記エンドドメインが、ヒトCD3ζエンドドメインを含む、請求項1に記載のCAR。
- 前記少なくとも1つの共刺激ドメインが、ヒトの4-1BB細胞内セグメント、CD28細胞内セグメント、CD40細胞内セグメント、ICOS細胞内セグメント、MyD88細胞内セグメント、OX-40細胞内セグメントのいずれか、またはこれらの任意の組み合わせを含む、請求項1に記載のCAR。
- 前記少なくとも1つの共刺激ドメインが、ヒトの4-1BB共刺激ドメインを含む、請求項11に記載のCAR。
- 前記ヒトCD3ζエンドドメインが、配列番号18008のアミノ酸配列を含む、請求項10に記載のCAR。
- 前記ヒト4-1BB共刺激ドメインが、配列番号18012のアミノ酸配列を含む、請求項12に記載のCAR。
- 前記ヒンジが、ヒトのCD8α配列、IgG4配列、CD4配列、またはそれらの任意の組み合わせに由来するアミノ酸配列を含む、請求項3に記載のCAR。
- 前記ヒンジが、ヒトCD8αに由来するアミノ酸配列を含む、請求項15に記載のCAR。
- ヒトCD8αに由来する前記配列が、配列番号18014のアミノ酸配列を含む、請求項16に記載のCAR。
- 請求項1に記載のCARと、医薬として許容可能な少なくとも1つの担体を含む組成物。
- 請求項1に記載のCARをコードする核酸配列を含むトランスポゾン。
- 請求項19に記載のトランスポゾンを含む組成物。
- 請求項1に記載のCARをコードする核酸配列を含むベクター。
- 請求項21に記載のベクターを含む組成物。
- 請求項1に記載のCARを含む細胞。
- 請求項19に記載のトランスポゾンを含む細胞。
- 請求項21に記載のベクターを含む細胞。
- 免疫細胞である、請求項23に記載の細胞。
- 前記免疫細胞が、T細胞、ナチュラルキラー(NK)細胞、ナチュラルキラー(NK)様細胞、サイトカイン誘導キラー(CIK)細胞、造血前駆細胞、末梢血(PB)由来T細胞、臍帯血(UCB)由来T細胞のいずれかである、請求項26に記載の細胞。
- 自己由来である、請求項23に記載の細胞。
- 細胞の集団を含む組成物であって、前記集団の複数の細胞が、請求項23に記載の細胞を含む組成物。
- 改変されたT細胞の集団を製造する方法であって、
(a)請求項1に記載のCARをコードする核酸配列を含む組成物を、複数のT細胞に導入することにより、改変されたT細胞の集団を生成させ;
(b)この改変されたT細胞の集団を、前記CARをコードする核酸配列の組み込みに適した条件下で培養し;
(c)細胞表面に前記CARを発現する前記改変されたT細胞の集団からの少なくとも1個の細胞を増殖させること、および/または選択すること
を含む方法。 - 配列番号18070のアミノ酸配列を含む、請求項1に記載のCAR。
- (a)ヒトCD8αシグナルペプチド及び抗原認識領域を含むエクトドメインであって、ここで前記抗原認識領域が、PSMAに特異的に結合する少なくとも1つのセンチリンを含む、エクトドメインと;
(b)ヒトCD8αヒンジドメインを含むヒンジドメインと;
(c)ヒトCD8α膜貫通ドメインを含む膜貫通ドメインと;
(d)ヒト4-1BB共刺激ドメイン及びヒトCD3ζエンドドメインを含むエンドドメイン、
を含み、
PSMAに特異的に結合する前記少なくとも1つのセンチリンが、配列番号18002のアミノ酸配列を含む、キメラ抗原受容体(CAR)。 - 前記ヒトCD8αシグナルペプチドが配列番号18004のアミノ酸配列を含み、
前記ヒトCD8αヒンジドメインが配列番号18014のアミノ酸配列を含み、
前記ヒトCD8α膜貫通ドメインが配列番号18006のアミノ酸配列を含み、
前記ヒト4-1BB共刺激ドメインが配列番号18012のアミノ酸配列を含み、そして
前記ヒトCD3ζエンドドメインが配列番号18008のアミノ酸配列を含む、
請求項32に記載のCAR。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862639978P | 2018-03-07 | 2018-03-07 | |
US62/639,978 | 2018-03-07 | ||
US201862745151P | 2018-10-12 | 2018-10-12 | |
US62/745,151 | 2018-10-12 | ||
US201862783140P | 2018-12-20 | 2018-12-20 | |
US62/783,140 | 2018-12-20 | ||
PCT/US2019/021224 WO2019173636A1 (en) | 2018-03-07 | 2019-03-07 | Cartyrin compositions and methods for use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021516958A JP2021516958A (ja) | 2021-07-15 |
JP7399866B2 true JP7399866B2 (ja) | 2023-12-18 |
Family
ID=66182630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020546322A Active JP7399866B2 (ja) | 2018-03-07 | 2019-03-07 | CARTyrin組成物とその利用方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210107993A1 (ja) |
EP (1) | EP3762106A1 (ja) |
JP (1) | JP7399866B2 (ja) |
KR (1) | KR20200140270A (ja) |
CN (1) | CN112601583A (ja) |
AU (1) | AU2019230192A1 (ja) |
BR (1) | BR112020018049A2 (ja) |
CA (1) | CA3092947A1 (ja) |
IL (1) | IL277079A (ja) |
MX (1) | MX2020009309A (ja) |
SG (1) | SG11202008659TA (ja) |
TW (1) | TW202017592A (ja) |
WO (1) | WO2019173636A1 (ja) |
ZA (1) | ZA202005556B (ja) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10961310B2 (en) | 2017-03-15 | 2021-03-30 | Pandion Operations, Inc. | Targeted immunotolerance |
CN108728477B (zh) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | 一种高效的转座突变系统及构建方法 |
BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US20210189337A1 (en) * | 2018-03-28 | 2021-06-24 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector t cells |
EP3847197A1 (en) * | 2018-09-05 | 2021-07-14 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
US20220042038A1 (en) | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
CN114679909A (zh) | 2019-05-20 | 2022-06-28 | 潘迪恩运营公司 | MAdCAM靶向的免疫耐受 |
CA3149892A1 (en) | 2019-09-05 | 2021-03-11 | Eric M. Ostertag | Allogeneic cell compositions and methods of use |
AU2020363697A1 (en) * | 2019-10-07 | 2022-04-07 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
US20230079955A1 (en) | 2019-12-20 | 2023-03-16 | Poseida Therapeutics, Inc. | Anti-muc1 compositions and methods of use |
GB201919019D0 (en) * | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
US20230085945A1 (en) * | 2020-02-25 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Orthogonal safety switches to eliminate genetically engineered cells |
JP2023515692A (ja) | 2020-03-04 | 2023-04-13 | ポセイダ セラピューティクス,インコーポレイティド | 代謝性肝障害の治療のための組成物と方法 |
EP4118107A1 (en) | 2020-03-11 | 2023-01-18 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
CN111458517B (zh) * | 2020-03-13 | 2022-08-16 | 深圳大学 | Selenof作为阿尔茨海默病药物靶点的应用 |
US20210324332A1 (en) | 2020-03-27 | 2021-10-21 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
BR112022020333A2 (pt) | 2020-04-10 | 2022-11-22 | Juno Therapeutics Inc | Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b |
IL297025A (en) | 2020-04-14 | 2022-12-01 | Poseida Therapeutics Inc | Preparations and methods for use in cancer treatment |
CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
US20240000969A1 (en) | 2020-10-21 | 2024-01-04 | Poseida Therapeutics San Diego | Compositions and methods for delivery of nucleic acids |
US20220168407A1 (en) | 2020-11-05 | 2022-06-02 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
CN112480242B (zh) * | 2020-12-04 | 2023-06-06 | 中国人民解放军陆军军医大学 | Spink7蛋白在制备预防和/或治疗溃疡性结肠炎的药物中的应用 |
CN112574291B (zh) * | 2020-12-14 | 2022-10-21 | 上海交通大学 | 一种生物活性肽shrkfsaprhgslgflpr及其制备方法和应用 |
CN112625142B (zh) * | 2021-02-03 | 2023-05-09 | 郑州大学第一附属医院 | Cxcl9修饰的car-t结构及其应用 |
WO2022170184A1 (en) * | 2021-02-05 | 2022-08-11 | University Of Cincinnati | Lipocalin 10 as a therapeutic agent for inflammation-induced organ dysfunction |
CA3208993A1 (en) | 2021-02-23 | 2022-09-01 | Joshua RYCHAK | Compositions and methods for delivery of nucleic acids |
US20240060090A1 (en) | 2021-02-23 | 2024-02-22 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
WO2022187671A1 (en) | 2021-03-04 | 2022-09-09 | Poseida Therapeutics, Inc. | Compositions and methods for the treatment of hemophilia |
AU2022253223A1 (en) * | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
AU2022257093A1 (en) | 2021-04-16 | 2023-11-02 | Celgene Corporation | T cell therapy in patients who have had prior stem cell transplant |
EP4082560A1 (en) * | 2021-04-27 | 2022-11-02 | Academia Sinica | Methods of treating hypertriglyceridemia or hypertriglyceridemia related diseases |
CN115477705B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用 |
WO2023060089A2 (en) | 2021-10-04 | 2023-04-13 | Poseida Therapeutics, Inc. | Transposases and uses thereof |
WO2023060088A1 (en) | 2021-10-04 | 2023-04-13 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
CN114716564B (zh) * | 2021-12-20 | 2023-02-28 | 四川大学华西医院 | 基于sectm1构建的嵌合抗原受体免疫细胞制备及其应用 |
CN113999873B (zh) * | 2021-12-31 | 2022-05-20 | 北京市疾病预防控制中心 | 一种基因修饰的非人动物的构建方法及其应用 |
CN114470225B (zh) * | 2022-01-20 | 2023-09-12 | 苏州市立医院 | 一种重组人cdc5l融合蛋白水凝胶、制备方法及应用 |
WO2023141576A1 (en) | 2022-01-21 | 2023-07-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
CN114113639B (zh) * | 2022-01-29 | 2022-04-19 | 北京大有天弘科技有限公司 | 一种血型抗体检测方法及其应用 |
WO2023152498A1 (en) | 2022-02-09 | 2023-08-17 | Horizon Discovery Limited | Polynucleotides with selection markers |
WO2023164573A1 (en) | 2022-02-23 | 2023-08-31 | Poseida Therapeutics, Inc. | Genetically modified cells and methods of use thereof |
CN114573678B (zh) * | 2022-03-11 | 2022-12-27 | 中山大学 | 一种Rheb蛋白激活剂及其应用 |
CN114644685B (zh) * | 2022-04-07 | 2023-07-04 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗hnRNPK蛋白RNA结合活性的多肽HIP-15及其应用 |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
CN114748498A (zh) * | 2022-05-13 | 2022-07-15 | 南京大学 | 针对CBFβ的shRNA在制备治疗结直肠癌药物中的应用 |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023235897A2 (en) * | 2022-06-03 | 2023-12-07 | Oyster Point Pharma. Inc. | Aav vector encoding diamine oxidase and uses thereof |
WO2024036273A1 (en) | 2022-08-11 | 2024-02-15 | Poseida Therapeutics, Inc. | Chimeric cd8-alpha co-receptor compositions and methods of use |
WO2024073440A1 (en) | 2022-09-27 | 2024-04-04 | Genentech, Inc. | Inhibition of genotoxic stress to improve t cell engineering |
CN116574193A (zh) * | 2023-05-10 | 2023-08-11 | 浙江大学 | 一种可抑制肿瘤坏死因子的简化巨球蛋白及合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
WO2016179534A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen binding fibronectin type iii domains |
WO2018014038A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
ATE238035T1 (de) | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | Perforierte mikropartikel und deren verwendung |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
EP2465538A3 (en) * | 2004-10-21 | 2013-11-20 | Ono Pharmaceutical Co., Ltd. | Use of immunesuppressant receptor |
US10927384B2 (en) | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
GB201416960D0 (en) * | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
GB201602563D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
KR20190101979A (ko) * | 2016-12-02 | 2019-09-02 | 유니버시티 오브 써던 캘리포니아 | 합성 면역 수용체 및 이의 사용 방법 |
-
2019
- 2019-03-07 EP EP19717987.2A patent/EP3762106A1/en active Pending
- 2019-03-07 US US16/977,547 patent/US20210107993A1/en active Pending
- 2019-03-07 TW TW108107666A patent/TW202017592A/zh unknown
- 2019-03-07 AU AU2019230192A patent/AU2019230192A1/en active Pending
- 2019-03-07 BR BR112020018049-1A patent/BR112020018049A2/pt unknown
- 2019-03-07 JP JP2020546322A patent/JP7399866B2/ja active Active
- 2019-03-07 CA CA3092947A patent/CA3092947A1/en active Pending
- 2019-03-07 CN CN201980030393.1A patent/CN112601583A/zh active Pending
- 2019-03-07 SG SG11202008659TA patent/SG11202008659TA/en unknown
- 2019-03-07 MX MX2020009309A patent/MX2020009309A/es unknown
- 2019-03-07 WO PCT/US2019/021224 patent/WO2019173636A1/en unknown
- 2019-03-07 KR KR1020207028511A patent/KR20200140270A/ko unknown
-
2020
- 2020-09-01 IL IL277079A patent/IL277079A/en unknown
- 2020-09-08 ZA ZA2020/05556A patent/ZA202005556B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
WO2016179534A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen binding fibronectin type iii domains |
WO2018014038A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
Non-Patent Citations (3)
Title |
---|
Production of Universal Anti-BCMA CAR T Cells with Reduced Alloreactivity, but Potent Effector Function for the Treatment of Multiple Myeloma,59th ASH Annual Meeting & Exposition [online],2017年,[令和5年1月26日検索],http://cms.cws.net/content/beta.myelomasociety.org/files/2017ash/Shedlock,%20D-171210%20Poseida%20ASH%20for%20IMS.PDF |
PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model,Journal for ImmunoTherapy of Cancer,2017年,Vol.5, Suppl. 2,p.236-237, P490,32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two |
Versatile CAR T-cells for cancer immunotherapy,Contemp Oncol (Pozn).,2018年03月,Vol.22, No.1A,p.73-80 |
Also Published As
Publication number | Publication date |
---|---|
US20210107993A1 (en) | 2021-04-15 |
CN112601583A (zh) | 2021-04-02 |
TW202017592A (zh) | 2020-05-16 |
RU2020132750A (ru) | 2022-04-07 |
WO2019173636A1 (en) | 2019-09-12 |
BR112020018049A2 (pt) | 2020-12-29 |
ZA202005556B (en) | 2024-03-27 |
WO2019173636A9 (en) | 2020-11-05 |
KR20200140270A (ko) | 2020-12-15 |
CA3092947A1 (en) | 2019-09-12 |
MX2020009309A (es) | 2021-01-08 |
IL277079A (en) | 2020-10-29 |
JP2021516958A (ja) | 2021-07-15 |
AU2019230192A2 (en) | 2020-10-22 |
EP3762106A1 (en) | 2021-01-13 |
AU2019230192A1 (en) | 2020-10-08 |
SG11202008659TA (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7399866B2 (ja) | CARTyrin組成物とその利用方法 | |
AU2018393110B2 (en) | VCAR compositions and methods for use | |
CN111727256A (zh) | 用于嵌合配体受体(clr)-介导的条件性基因表达的组合物和方法 | |
CN113383018A (zh) | 同种异体细胞组合物和使用方法 | |
JP2019524721A (ja) | キメラ抗原受容体および使用方法 | |
CN116425882A (zh) | 嵌合蛋白 | |
JP2020510101A (ja) | 造血幹細胞の選択的除去と置換のための組成物と方法 | |
US20220042038A1 (en) | Nanotransposon compositions and methods of use | |
KR20180092989A (ko) | 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도 | |
KR20230002681A (ko) | 대형 아데노바이러스 페이로드의 통합 | |
RU2792187C2 (ru) | Композиции cart-иринов и способы их применения | |
WO2020077357A1 (en) | Compositions and methods for increasing transposition frequency | |
JP2022547866A (ja) | 同種異系細胞組成物と使用方法 | |
WO2023060088A1 (en) | Transposon compositions and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220304 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230807 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7399866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |